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Abstract 
The study aims to utilize trehalose particles as an inert fine carrier to improve 
DPI aerosolization performance, diversify the potential delivery of new drugs in DPI 
formulations and the feasibility of bringing high drug dose into the lungs. Inhalable 
fine trehalose particles were engineered by jet milling and spray drying to reach 
different physicochemical characteristics that were assessed and related to the 
evaluated aerosolization performance of the prepared formulations with model drugs. 
The delivery of high dose of oseltamivir phosphate (OP) antiviral drug was further 
improved in formulations of 25% fine trehalose particles reaching about 75% fine 
particle fraction (FPF) as assessed by cascade impaction. The aerosol generation of 
model COPD inhalable drugs was evaluated on the bases of their hydrophilic and 
hydrophobic nature affecting their agglomeration behavior with trehalose fine 
particles. Accordingly, different trehalose batches presenting different 
physicochemical characteristics such as particle size, morphology, surface energy, 
crystallinity, and hydration exhibited variation in aerosolization performance from 1% 
till 80% FPF as assessed by impaction. In summary, tailored DPI formulations are 
essential for every active pharmaceutical ingredient and particle engineering of both 
the carrier and the drug control the outcome of the formulation performance. 
Trehalose particles have shown compatibility, stability and aerosol generation 
effectiveness with a variety of API types and ratios. This concludes that fine trehalose 
particles have the potential for being an outstanding inert and safe carrier for the 
delivery of new and current API in DPI formulations. 
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1.1 General Introduction 
The successful delivery of safe and effective active pharmaceutical ingredients 
(API) through the pulmonary route is dependent on; delivery device, drug formulation 
and the biology of the respiratory system (Forbes and Ehrhardt, 2005; Gradon and 
Sosnowski, 2014). The respiratory system is mainly composed of a gas exchange 
organ (Lungs), airway passages and a pump (chest wall) that ventilates the lungs. 
The major function is the gas exchange (external respiration) which is the absorption 
of O2 and removal of CO2 from the body. In addition, the respiratory system has 
different metabolic and endocrine functions (Barrett and Ganong, 2010; Despopoulos 
and Silbernagl, 2003). The Lungs contain around 300 million alveoli (thin-walled air 
sacs) about 0.3mm in diameter located on the terminal branches of the bronchial 
tree. They are surrounded by a dense network of pulmonary capillaries and have a 
total surface area of about 70 - 100 m2 (Barrett and Ganong, 2010; Costanzo, 2006; 
Despopoulos and Silbernagl, 2003). Due to the large surface area of the alveolar 
epithelium, the short air to blood pathway and permeability to many substances, the 
pulmonary deposition of aerosols represents an efficient, rapid and non-invasive 
alternative for the delivery of many drugs (Lahnstein et al., 2008) .  
For a moment we might consider inhalation therapy as a modern approach to 
drug delivery, but actually the historical review recorded the development of 
inhalation therapy starting from ancient Egyptian times about 3500 years ago 
(Sanders, 2007). Furthermore, a breakthrough in inhalation drug delivery 
development started since the early 19th century. Simple inhalation devices and 
aerosols containing various drugs have been used for the treatment of respiratory 
disorders. In addition, scientific analysis of inhalation drug delivery concepts of 
particles deposition in the human respiratory tract was observed and documented in 
1881 by Tyndall (Heyder et al., 1986). 
Inhalation therapy was considered mainly for pulmonary disease such as 
cystic fibrosis, asthma, chronic obstructive pulmonary diseases (COPD) and even 
lung cancer. The local pulmonary deposition and delivery of the administered drug 
facilitates a targeted treatment of respiratory diseases without the need for high dose 
exposures by other routes of administration and consequently reduced systemic side 
effects (Beck-Broichsitter et al., 2009; Minne et al., 2008; Pilcer and Amighi, 2010). 
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Recently, inhalation therapy has grabbed the attention for the administration of 
systematically API that is poorly absorbed by gastrointestinal tract or undergoes 
presystemic metabolic degradation such as polypeptides, proteins, steroids, genes 
and vaccines (Stegemann et al., 2013).  
1.2 Respiratory System 
1.2.1 Structure of the Respiratory System 
The respiratory system includes the lungs and a series of airways that connect 
the lungs to the external environment. The structures of the respiratory system as 
illustrated in Figure ‎1-1 are subdivided into a conducting zone, which brings air into 
and out of the lungs, and a respiratory zone lined with alveoli, where gas exchange 
occurs. The functions of the conducting and respiratory zones and the structures 
lining them also differ. The conducting zone includes the nose, nasopharynx, larynx, 
trachea, bronchi, bronchioles, and terminal bronchioles. These structures function to 
bring air into and out of the respiratory zone for gas exchange and to warm, humidify, 
and filter the air before it reaches the critical gas exchange region. The trachea is the 
main conducting airway. The trachea divides into two bronchi, one leading into each 
lung, which divide into two smaller bronchi, which divide again. Ultimately, there are 
23 such divisions into increasingly smaller airways. The conducting airways are lined 
with mucus-secreting and ciliated cells that function to remove inhaled particles. 
Although large particles usually are filtered out in the nose, small particles may enter 
the airways, where they are captured by mucus, which is then swept upward by the 
rhythmic beating of the cilia (Barrett and Ganong, 2010; Costanzo, 2006) 
 The respiratory zone includes the respiratory bronchioles, the alveolar ducts, 
and the alveolar sacs that are lined with alveoli, the main site for gas exchange. The 
respiratory bronchioles are transitional structures. Like the conducting airways, they 
have cilia and smooth muscle, but they also are considered part of the gas exchange 
region because alveoli occasionally bud off their walls. The alveolar ducts are 
completely lined with alveoli, but they contain no cilia and little smooth muscle. The 
alveolar ducts terminate in alveolar sacs, which also are lined with alveoli. The 
alveolar walls are rimmed with elastic fibers and lined with epithelial cells, called type 
I and type II pneumocytes (Barrett and Ganong, 2010; Costanzo, 2006)  
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1.2.2 Mechanics of breathing 
Pressure differences between the alveoli and the environment are the driving 
forces for the exchange of gases that occurs during ventilation. Alveolar pressure (PA 
= intrapulmonary pressure) must be lower than the barometric pressure (PB) during 
inspiration (breathing in), and higher during expiration (breathing out). If PB is defined 
as zero, the alveolar pressure is negative during inspiration and positive during 
expiration. These pressure differences are created through coordinated movement of 
the diaphragm and chest (thorax) as shown in Figure ‎1-2, resulting in an increase in 
lung volume (Vpulm) during inspiration and a decrease during expiration. The 
inspiratory muscles consist of the diaphragm, scalene muscles, and external 
intercostal muscles. Their contraction lowers (flattens) the diaphragm, raises and 
expands the chest, thus expanding the lungs. Inspiration is therefore active. The 
external intercostal muscles and accessory respiratory muscles are activated for 
 Particle deposition 
size range 
Impaction (≥5µm) 
Gravitational 
Sedimentation (0.5 - 
5µm) 
Diffusion (≤0.5µm) 
Figure ‎1-1: Respiratory zones with branching hierarchy showing the particle deposition 
mechanism in different areas based on aerodynamic particle size (adapted from Barrett and 
Ganong 2010) 
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deep breathing. During expiration, the diaphragm and other inspiratory muscles relax, 
thereby raising the diaphragm and lowering and reducing the volume of the chest and 
lungs. Since this action occurs primarily due to the intrinsic elastic recoil of the lungs, 
expiration is passive at rest and the lung collapses like a balloon and expels its air 
through the trachea whenever there is no force to keep it inflated. In deeper 
breathing, active mechanisms can also play a role in expiration: the internal 
intercostal muscles contract and the diaphragm is pushed upward by abdominal 
pressure created by the muscles of the abdominal wall (Barrett and Ganong, 2010; 
Despopoulos and Silbernagl, 2003) 
 
Figure ‎1-2: Movement of Muscles, Diaphragm and Rib Cage during inhalation and exhalation 
(Despopoulos and Silbernagl, 2003). 
1.2.3 Lung function 
At the end of normal quiet expiration, the lung–chest system returns to its 
intrinsic resting position. About 0.5 L of air is taken in with each breath during normal 
quiet respiration; this is called the resting tidal volume (VT). Inspiration can be 
increased by another 3 L on forced (maximum) inspiration; this is called the 
inspiratory reserve volume (IRV). Likewise, expiration can be increased by about 1.2 
-1.7 L more on forced (maximum) expiration. This is called the expiratory reserve 
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volume (ERV). These reserve volumes are used during strenuous physical exercise 
and in other situations where normal tidal volumes are insufficient. Even after forced 
expiration, about 1.3 L of air remains in the lungs; this is called the residual volume 
(RV). Lung capacities are the sum of the individual lung volumes. The vital capacity 
(VC) is the maximum volume of air that can be moved in and out in a single breath. 
Therefore, VC = VT + IRV + ERV. The average 20-year-old male has a VC of about 
4.7 - 5.3 L. Normally the vital capacity decreases and residual volume increases with 
age. The total lung capacity (TLC) is the sum of VC and RV—on average 5.9 to 7 L. 
The functional residual capacity is the sum of ERV and RV. The inspiratory capacity 
is the sum of VT and IRV. All numerical values of these volumes apply under body 
temperature–pressure saturation (BTPS) conditions (Barrett and Ganong, 2010; 
Despopoulos and Silbernagl, 2003). 
1.3 Respiratory drug delivery 
1.3.1 Factors controlling lung deposition 
API particles from inspired aerosols can either be administered through the 
nasal or oral routes. Inspired particles deposition refers to the probability of 
distributing the particles among the respiratory system and becoming in contact with 
the inner lining. The key controllers governing lung deposition may be divided into 
those related to the physicochemical properties of the droplets or particles being 
delivered, the mechanical aspects of aerosol dispersion usually associated with the 
delivery device, and the physiological and anatomical considerations associated with 
the biology of the lungs (Florence and Siepmann, 2009; Gradon and Sosnowski, 
2014; Heyder et al., 1986). 
The common target for inhalation therapies is having particles that mostly able 
to pass the extrathoracic region and the tracheobronchial tree to deposit in the 
alveolar region for maximum therapeutic effect. The Particle aerodynamic size is one 
of the most important design variables in an aerosol formulation, along with shape, 
density, electrical charge and hygroscopicity. In fact, the three principal mechanisms 
of particle deposition in the respiratory tract rely on the size of the inhaled particles 
illustrated in Figure ‎1-3. Impaction is the inertial deposition of a particle onto an 
airway surface. It occurs principally at or near airway bifurcations, most commonly in 
extrathoracic and large conducting airways, where flow velocities are high and where 
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rapid changes in the direction of bulk airflow often take place, generating 
considerable inertial forces. The probability of impaction increases with increasing air 
velocity, rate of breathing, particle size (>5 µm) and density. Gravitational 
sedimentation is an important mechanism for deposition of particles over 0.5 µm and 
below 5 µm in size in the small conducting airways where the air velocity is low. 
Deposition due to gravity increases with enlarging particle size and longer residence 
times but decreases as the breathing rate increases. Submicron-sized particles 
(especially those less than 0.5µm) acquire a random motion caused by the impact of 
surrounding air molecules. This Brownian motion may then result in particle 
deposition by diffusion, especially in small airways and alveoli, where bulk airflow is 
very low (Florence and Siepmann, 2009; Pilcer and Amighi, 2010; Stegemann et al., 
2013).  
1.3.2 Categories of oral inhalation devices 
Orally inhaled drug delivery devices are divided into 3 main categories; 
nebulizers, pressurized metered dose inhalers (pMDI), and dry powder inhalers 
(DPI). Each category presents pros and cons which accordingly chosen for 
therapeutic needs.  
Nebulizers exploit the energy produced by air-jet or ultrasonic techniques to 
aerosolize the active pharmaceutical ingredient (API) that is held in a liquid form. 
Patients use nebulizers most often in hospitals or at home, since they are less 
portable compared to the other types and require energy source. They are capable of 
delivering high API doses such as 300mg in case of antibiotics but consume more 
time. Furthermore they require frequent disinfection and maintenance (Geller, 2005; 
Pilcer and Amighi, 2010). 
Metered dose inhalers are the primary choice for asthma therapy as they are 
small, portable, multidose and quick to use. The API is either dissolved or suspended 
in a liquefied propellant under pressure in a canister. On the other hand, several 
problems were encountered in pMDIs development, one of which is the physical 
stability of the API held by the propellant in the liquid form. Also the technique to 
coordinate the actuation and inhalation required is considered very difficult for 
patients to use efficiently (Dolovich and Dhand, 2011; Geller, 2005; Pilcer and 
Amighi, 2010).   
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Dry powder inhalers are available in many forms; in general they are breath 
actuated with no propellant, and the API is kept in a one phase dry solid state.  DPIs 
appear to be the most promising for future use as they are portable, easy to operate 
and low-cost devices with improved stability of the formulation. One drawback is the 
inability of patients with inadequate inspiratory flow to activate the DPI (Geller, 2005; 
Rahimpour et al., 2014; Telko and Hickey, 2005). 
1.3.3 DPI Design 
In 1864, Alfred Newton has introduced the first dry powder inhaler, setting the 
main principle that the powder need to be pulverized and kept dry (Sanders, 2007). 
Later, since the invention of the Spinhaler® and its introduction on the market in 
1968, the technology has significantly developed and a wide range of devices are 
currently available in the market or under research. Basically in a passive DPI device 
when breath actuated, the air flow and the inhalers’ resistance cause a turbulent 
energy that emit the powder formulation dose to be aerosolized through a grid where 
the particles are dispersed and de-agglomerated releasing the API fines to reach the 
deep lungs as illustrated in Figure  1-3 (Islam and Cleary, 2012; Pilcer and Amighi, 
2010; Telko and Hickey, 2005).  
DPIs can be categorized into two main types based on the formulation 
packaging; single doses as that contained in capsules or multiple dose devices that 
contain the formulation in a foil blister or a metered reservoir, a list of some available 
DPI devices is shown in Figure ‎1-4. In contrast to the single dose inhalers, the 
multiple dose DPIs such as Turbuhaler and Easyhaler avoid the inconvenience of 
loading a capsule immediately before each use. Furthermore a metering system is 
often fitted and a measured dose is loaded into the air flow-path just before 
inhalation. On the other hand, since the API is stored within the multiple doses 
device, the design must ensure protection against atmospheric humidity. In view of 
that, most multiple dose devices are not refillable and this increases the therapeutic 
expense. Even though multiple dose DPIs are protected against the exposure effects 
of atmospheric humidity, the temperature and humidity at the time of use may affect 
performance including dose variation (Islam and Cleary, 2012; Pilcer and Amighi, 
2010; Telko and Hickey, 2005).  
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Figure ‎1-3: Principle mechanism of DPI design (Telko and Hickey, 2005). 
Another categorization can be based on the device aerodynamic resistance or 
the pressure drop required for aerosolizing the formulation; it can be of high, medium 
or low resistance. The patients’ inspiratory action is the drive to reach the required 
flow rate against this resistance to efficiently aerosolize and disperse the powder. 
Consequently, a pressure drop of a normal lung function which is about 4 kPa would 
lead to a flow rate of 90 to 100L/min in a model type for low resistance as the 
Aerolizer, flow rate of 40 to 60 in a moderate resistance inhaler such as the 
Easyhaler, and less than 40 L/min in high resistance inhalers such as Handihaler. 
Patients with severely impaired lung function and young children may not be able to 
sufficiently use high resistance devices due to possible incomplete dispersion and 
aerosolization of the DPI formulation (Gradon and Sosnowski, 2014; Islam and 
Cleary, 2012; Srichana et al., 1998; Tiddens et al., 2006).  
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1) Aerolizer® 2) HandiHaler® 3) Novolizer® 
  
 
 
4) Turbuhaler® 5) Easyhaler® 6) Diskus® 
 
Figure ‎1-4: List of some DPI devices available in the market; Single dose Capsule Devices; 1) 
Aerolizer® (low resistance), 2) HandiHaler® (high resistance), Multi-dose reservoir/cartridge; 3) 
Novolizer® (medium resistance), 4) Turbuhaler® (medium resistance), 5) Easyhaler® (medium 
Resistance), Multi-doses encapsulated in foil blisters; 6) Diskus® (low resistance). 
As collected from the literature, the main characteristics for an Ideal DPI would be: 
 Accurate and uniform dose delivery that is independent on the respiratory air 
flow. 
 Optimal formulation that deliver API particles deep to the lungs with minimal 
retention in the device. 
 Multi dose inhalers with consistent and reproducible dose delivery.  
 Suitable for wide range of API either pulmonary local targeting or systemic into 
the blood, maintaining physicochemical stability. 
 User friendly in terms of portability, economic, and feedback mechanism for 
dosage administration. 
Unfortunately, there is no current Ideal DPI. However research is growing in two main 
directions; the development of DPI formulations with optimum aerosolization behavior 
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and the development of efficient and reliable devices. (Dolovich and Dhand, 2011; 
Islam and Cleary, 2012; Islam and Gladki, 2008; Telko and Hickey, 2005) 
1.3.4 DPI formulations 
For the API particles to reach the inner lung, they must have an aerodynamic 
size range of 1-5 µm. These very small particles exhibit large surface area that gives 
cohesive and adhesive properties hindering efficient aerosolization. Furthermore, 
model inhaled drugs are mainly given in µg doses which are very small amount to be 
inhaled alone efficiently. Accordingly, the basic approach to overcome such problems 
is to formulate the fine drug with a coarser carrier (about 95% w/w) to facilitate the 
flowability and dispersion (Tee et al., 2000; Andrade et al., 2013). 
Traditionally, lactose monohydrate is the main choice as a carrier. It is mass 
produced from natural sources with acceptable low toxicity. In addition, lactose is a 
relatively simple disaccharide with a range of grades commercially available based 
on the particle size distribution (Traini et al., 2006; Andrade et al., 2013). 
As particle size distribution affects a drug’s deposition in the lungs, separation 
of the small solid particles used in dry powder inhalers is the most important 
performance characteristic for effective aerosol generation. To separate particles, the 
specific force of interaction must be overcome. There are four major forces of 
interaction between particles: mechanical interlocking due to surface asperities, 
capillary forces from the presence of water, electrostatic forces arising from the 
insulating nature of the material and van der Waals forces from the fundamental 
electromagnetic nature of matter (Gradon and Sosnowski, 2014; Pilcer and Amighi, 
2010). The major forces of interaction present a barrier to the particles’ flow and 
dispersion (Florence and Siepmann, 2009). Van der Waals forces are derived from 
the energy of interaction between two molecules, the shorter the distance between 
particles the higher the attractive forces and the higher the agglomeration. Since the 
separation distance plays a key role in the strength of van der Waals forces, it can be 
controlled by surface shape (e.g.: surface roughing) and use of fine spacer 
particulates (e.g.: fine lactose excipient) (Kou et al., 2012). Electrostatic forces must 
be considered for poor conductors as pharmaceutical products. Furthermore, two 
adjacent solid surfaces give rise to contact potential and in turn electrostatic attractive 
forces that increase powder aggregation. Capillary forces increase in relationship to 
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the relative humidity (RH) of the ambient air. At greater than 65% RH, water 
condenses in the space between adjacent particles. This leads to liquid bridges 
causing attractive forces due to the surface tension of the water. In addition, surface 
asperities might increase the potential for mechanical interlocking of particles, which 
will influence the aggregation state and ease of dispersion of particles (Florence and 
Siepmann, 2009).  
The aerodynamic characteristics of the dose emitted from a dry powder inhaler 
(DPI) are determined by the degree of de-aggregation of the dose inside the inhaler 
during the inhalation maneuver (Nadarassan et al., 2010). In such preparations, the 
inspiratory force of the patient must overcome the adhesion forces between drug and 
carrier particles to aerosolize particles (Thi et al., 2008). 
1.3.5 Current DPI formulation approaches and performance 
limitations  
As stated earlier, physicochemical properties control the particle interactions 
which in turn determine the aerodynamic behavior of the DPI formulation. Optimizing 
the particles (size, morphology and structure) can be done through the choice of the 
production method. Particles can be engineered by spray drying (SD), spray freeze 
drying (SFD), supercritical fluid technologies (SCF), and even directly pulverized by a 
jet mill. Each production method has its advantages and drawbacks, depending 
mainly on the type of API being processed (Ashurst et al., 2000; Gradon and 
Sosnowski, 2014; Pilcer and Amighi, 2010). Furthermore, selected API particles were 
able to stand alone in carrier free formulations, showing positive results that even 
reached the market as budesonide in Pulmicort®. In this case, micron sized 
budesonide particles were agglomerated into spheres to reach the required flow 
properties and de-agglomeration behavior upon aerosolization. However, alternative 
carriers other than lactose are required to be able to widen the range of API that can 
be administered as DPI and achieve better aerosolization performance. Why lactose 
cannot be used with all types of API? Clinically, lactose can be delivered to diabetic 
and lactose intolerant patients without causing problems. However, considering its 
physicochemical properties, lactose is a reducing sugar that can interact with 
functional groups of APIs such as formoterol, budesonide, proteins and peptides 
(Pilcer and Amighi, 2010; Rahimpour et al., 2014; Steckel and Bolzen, 2004).  
Theoretical Background 
13 
 Intensive studies have been conducted on alternative sugars as potential 
excipients for DPI such as D-mannitol, glucose monohydrate, trehalose dihydrate, 
erythritol, dextrose, maltose, sorbitol, maltitol, and xylitol. They were employed as the 
main coarse carriers with a particle size range of about 30 – 200 µm and as ternary 
fine additives to enhance aerosolization performance (Pilcer and Amighi, 2010; 
Rahimpour et al., 2014; Steckel and Bolzen, 2004; Tee et al., 2000).   
The performance of DPI is assessed in-vitro by impaction methods mainly, 
showing the fine particle fraction (FPF %) aerosolized that can reach the inner lung. 
Currently available inhalers from market and under research from literature give FPF 
range of 9% to 80% as collected by (Islam and Cleary, 2012). This shows the need of 
unconventional formulation designs improving aerosolization performance specifically 
for each API intended for pulmonary delivery.  
1.3.6 Trehalose 
Trehalose dihydrate is a disaccharide sugar that is commonly found in most 
life forms except mammals. It is produced as a cellular stress response factor due to 
its bio protective functions (Jain and Roy, 2009). It has been studied for its bio 
protection property specifically for dehydrated biological drugs such as proteins and 
peptides (Schebor et al., 2010). One of many studies, trehalose had an outstanding 
protective and stabilizing functions for spray dried immunoglobulin and their dry 
storage (Maury et al., 2005). On the other hand, attempts took place to utilize 
trehalose particles in improving DPI aerosolization performance. It is generally 
recognized as safe (GRAS) by the FDA as it has no potential to injure the lungs and 
easily cleared by metabolism (Pilcer and Amighi, 2010; Rahimpour et al., 2014). 
Unlike lactose, trehalose is a non-reducing sugar that does not cause degradation to 
specific molecules by Maillard reaction (Jain and Roy, 2009). Accordingly, trehalose 
has the edge of physical stability and compatibility with a wider formulation types. 
With particle engineering, prepared nano-porous micro-particles of trehalose showed 
positive results delivering protein drugs by DPI (Ogáin et al., 2011). Moreover, 
trehalose showed remarkable aerosolization performance as a carrier in DPI 
formulations in some studies with model pulmonary drugs; albuterol sulfate, 
ipratropium bromide monohydrate, disodium cromoglycate, and fluticasone 
propionate (Cline and Dalby, 2002; Mansour et al., 2010).  
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1.4 Aim of work 
The study aims to utilize trehalose particles as an inert fine carrier to improve 
DPI aerosolization performance, diversify the potential delivery of new drugs in DPI 
formulations and the feasibility of bringing high drug dose into the lungs. 
In a previous study to deliver oseltamivir phosphate (OP) antiviral drug as a 
DPI, trehalose formulations showed superior aerosolization performance over other 
formulations of lactose, mannitol, and glucose carriers. Hence the first chapter aims 
to characterize fine jet milled trehalose and to use it for optimized aerosolization of 
OP in dry powder inhalation formulations targeting enhanced therapeutics. Another 
aim was to evaluate the feasibility of bringing high drug doses into the lungs using 
trehalose as a fine carrier in low and medium resistance inhaler devices. 
As discussed previously, particle engineering plays an important role in 
physicochemical properties that directly affect the aerosolization performance. 
Hereafter, chapter two focuses on the production of trehalose spherical particles in 
an inhalation grade size with smooth surface aiming to investigate the effects of 
surface engineered spray dried trehalose.  
Aerosolization behavior is the main factor that decides whether a prepared DPI 
formula is accepted or not. Subsequently, the third chapter illustrates the 
aerosolization behavior of fine spray dried and fine jet milled trehalose carrier based 
DPI formulations with low dose model pulmonary drugs. It correlates the 
aerosolization performance to the carrier particle morphology, size, and surface 
energy produced under different factors. 
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2.1 Particle engineering and production 
2.1.1 Design of experiments 
Two designs of experiments were carried out for studying the inlet feed 
variables on the trehalose particle size produced by jet milling and spray drying as 
discussed later. The designs were conducted and evaluated by Modde® DOE 
software. 
2.1.2 Jet milling 
As described in reviews, jet milling is the most useful and traditional technique 
for particle size reduction, although there is no control over the produced particle 
crystalline morphology (Malcolmson and Embleton, 1998; Pilcer and Amighi, 2010). 
The technique was considered and described for micro-particle production from over 
10 years (Nykamp et al., 2002; Vatsaraj et al., 2003). Different APIs and trehalose 
batches were micronized by a fluid energy jet mill Jet-O-Mizer (Figure ‎2-1). To reach 
different target particle sizes it was controlled by two variables; grinding pressures (5 
- 10 Bar) and number of runs (1 - 2 runs). 10 gram sample of each powder was 
added into the feed. The particles are pushed into the milling chamber by high 
pressure pushing nozzle where the pusher nozzle was set one bar higher than the 
grinding nozzle. 
 
 
 
 
 
 
 
Sample Input 
Grinding Nozzle 
Pusher Nozzle 
Grinding Chamber 
Product Exit 
Figure ‎2-1: Jet mill schematic diagram 
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2.1.3 Spray drying 
Particle engineering is a very sophisticated field of science; spray drying is a 
well-established method for the production of dry powder engineered particles with 
controlled morphology (size, shape, structure and surface energy). The product 
characteristics can be modified by the process and formulation parameters as 
described by many studies (Gradon and Sosnowski, 2014; Nandiyanto and 
Okuyama, 2011; Vehring, 2008).  
All solutions prepared were spray dried with a Büchi B-290 Mini spray dryer. A 
nozzle tip of 0.7mm and nozzle screw cap of diameter 1.5mm were used. When 
spray drying aqueous solutions, the spray dryer was operated in the open mode, 
whereby the drying gas (compressed air) passes through the drying chamber and 
then is exhausted. When spray drying organic solutions as dichloromethane, the 
Büchi B-290 was operated in the closed mode, whereby the drying gas (nitrogen) is 
recycled to the drying chamber after precooling in a preheat exchanger and solvent 
condensation in a refrigerator unit (B-295 inert loop); in all cases the aspirator setting 
was 100%.  
For trehalose solutions, they were prepared in bi-distilled water in the 
concentrations of; 5, 10, 15, 20, 25, 30, 40 % (w/v). The inlet temperature setting 
range was: 75, 85, 95 and 105 °C. The pump rate setting was tested at 10, 15 and 
20%. The gas flow rate was set on the gas rotameter indicator at 30mm (500 Nl/h), 
40mm (670 Nl/h) and 50mm (840 Nl/h). 
Each of salbutamol sulphate and di-sodium cromoglycate was spray dried as 
5% (w/v) solution from bi-distilled water. The inlet temperature was 145°C, pump rate 
was 10% and gas flow set at 45mm (750 Nl/h). 
Budesonide was spray dried as 5% (w/v) solution in dichloromethane. The 
inlet temperature was 45°C, pump rate was 1% and gas flow set at 50mm (840 Nl/h).  
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2.2  Physicochemical characterization 
2.2.1 Particle size distribution 
For geometric particle size distribution analysis, a powder sample after 
micronization or spray drying was dispersed in a RODOS module at 3 bars 
(Sympatec GmbH, Clausthal-Zellerfeld, Germany). Fraunhofer theory was used to 
calculate the particle size distribution (PSD) from the scattered laser light as 
described by de Boer (de Boer, Gjaltema et al. 2002). The measurements were 
performed in triplicates and data acquisition and calculations made with Helos-
Sympatec Window X5 software. 
2.2.2 Differential scanning calorimeter 
Thermal properties of the different micronized and spray dried trehalose were 
investigated using a differential scanning calorimeter (Diamond DSC, Perkin Elmer, 
USA). Approximately 6-9mg of sample was accurately weighed into an aluminum pan 
and sealed with a lid into which one vent hole is pierced. The sample and reference 
(an identical pierced lid sealed pan, but empty) were heated at a rate of 10ºC/min or 
100ºC/min from -10ºC to 240ºC. The calorimeter head was flushed with nitrogen gas 
at 20 mlmin-3 during all measurements. For a further insight on the glass transition 
properties of spray dried trehalose, modulated DSC (mDSC) was performed using a 
step scan method each of 3° from -20°C to 120°C, at rate of 5°C/min. MDSC gives 
an enhanced interpretation and detection of glass transition for complex thermal 
events (Gill et al., 2010). Perkin Elmer – Pyris software was used for capture and 
analysis of data. 
2.2.3 Dynamic vapor sorption 
The moisture sorption characteristics of trehalose particles were assessed by 
DVS (DVS-HT, surface measurement systems Ltd., London, UK). Approximately 
40mg of each sample was weighed into the sample cell and subjected to two 0–90% 
relative humidity sorption cycles, over 10% RH increments. 
Methodology 
19 
2.2.4 X-Ray powder diffraction 
The crystalline structure of trehalose was analyzed before and after 
micronization and spray drying by X-ray diffraction. Samples were analyzed by X-ray 
diffractometer with a rotating anode (Stoe and Cie GmbH, Darmstadt, Germany) with 
a Cu-Kα source operated at 40 kV and 30mA. 
2.2.5 Specific surface area 
The specific surface area of the micronized trehalose particles were measured 
with the gas sorption analyzer (NOVA 2200, Quantachrome Corporation, USA). An 
eleven-point BET nitrogen adsorption isotherm analysis at 77 K was performed in 
triplicate after degassing the samples overnight under vacuum at room temperature. 
2.2.6 Fluidization energy 
The fluidization energy of the micronized trehalose was measured under 
aerated conditions by an FT4 Powder Rheometer (Freeman Technology, UK). For 
each run, 25mL of sample powder was analyzed in a 30mm bore borosilicate glass 
cylinder. The powders were evaluated using an automated aeration program that 
runs a sequence of tests at increasing levels of air velocity through the powder 
sample (0–10mms−1), with a conditioning cycle before each test cycle. The fluidization 
energy is determined when the flow energy plateau at increasing air flow velocities 
(Cordts and Steckel, 2012). 
2.2.7 Thermo gravimetric analysis 
Moisture content of trehalose dihydrate as obtained and finest micronized 
trehalose were measured by thermo-gravimetric analysis (TGA - TAC7/DX – Perkin 
Elmer, USA). Measurements are performed using 1–2mg of sample in an alumina 
crucible from 30ºC to 220º C at 10ºC min−1 heating rate under a nitrogen 
atmosphere. 
2.2.8 Scanning electron microscope 
Pure powders and blend morphologies were investigated using scanning 
electron microscopy (SEM, Carl Zeiss Microscopy GmbH). Samples were mounted 
on carbon sticky tabs and examined at different magnification power.  
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2.2.9 Inverse gas chromatography 
Inverse gas chromatography was used to determine the surface dispersive 
energies of powders. For all measurements, approximately 300-600mg was packed 
into a pre-silanized glass column (300mm×3mm internal diameter). Weights of each 
sample used for packing was chosen according to previous trials and errors for 
optimum iGC reading. By vertical tapping for at least 10 minutes using an iGC 
column packer, progress was visually monitored and tapping continued until no 
cracks, hollows or channels in the body of the powder bed were visible. Both ends of 
the columns were loosely stoppered with silanized glass wool. Prior to the 
measurements, pre-treatment was carried out for 2 h at 303K to remove impurities 
adsorbed on the surface. Helium with a gas flow rate of 10 sccm (standard cubic 
centimeter per minute) was used to carry different probes, and the retention times 
were detected with a flame ionization detector (FID). Dead volume calculations were 
based on the elution time of methane which was used at a concentration of 0.04 
(p/p°) (where p denotes the partial pressure and p° the saturation vapor pressure). 
The dispersive surface energies were determined by the pulse-varying probe 
method. Five alkane probes (Elutant) (GC grade hexane, heptane, octane, nonane 
and decane) were used to determine the dispersive surface energy (γD). Surface 
energy measurements at infinite dilution were performed in triplicate. The selection of 
conditioning time and temperature was based on preliminary experiments utilizing the 
method adopted from (Swaminathan et al., 2006).   
2.3 Preparation of DPI blends 
Targeting a high dose formulation, OP was mixed with different grade 
trehalose in the ratio of 3:1. On the other hand, as a standard of low dose 
formulations; SS, BU, and DSCG were each prepared in ratio 1: 5 formulations with 
different trehalose batches. All the binary DPI formulations were prepared first by 
geometric mixing and sieving followed by blending in a 30 cm3 stainless vessel using 
a turbula mixer at 42rpm for 10 min. Geometric mixing of the Carrier with API was 
performed to give equal distribution of the unequal amounts prior to blending. The 
powder of the lesser amount (i.e.; API) is mixed with similar amount of carrier. Then 
continued mixing with the remaining powder (i.e.: Carrier) in a similar additive 
manner. Afterwards the blending is repeated under same conditions and then passed 
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through final 355µm sized sieve for breaking down large agglomerates. Following 
blending and sieving, the drug homogeneity of all the formulations was assessed. 3 
samples top, middle and bottom were taken from each formulation dissolved in an 
appropriate solvent and drug concentration assessed using a spectrophotometer or 
HPLC assay. The whole preparation was done in an environmental controlled 
chamber at relative humidity (RH) around 40% and temperature below 25ºC. 
2.4 Aerosolization performance 
2.4.1 Aerosol dispersion for laser diffraction 
For each of the selected micronized trehalose samples and the OP-
formulations prepared, the PSD determined by laser diffraction utilizing two 
configurations: RODOS module and INHALER module. A Sympatec Helos 
(Sympatec GmbH, Clausthal-Zellerfeld, Germany) was used with an R2 lens. The 
INHALER module includes the Inhaler, throat and a pre-separator that is similarly 
assembled as the NGI and connected to a vacuum pump (Assembly shown in Figure 
‎2-4). The pre-separator is coated with a solution of Brij35:Ethanol:Glycerol at weight 
ratio of 15:51:34, respectively, to prevent powder particles from bouncing.  
De-agglomeration behavior of different micronized trehalose samples were 
assessed based on the comparison between PSD at a cutoff point of 5µm when fully 
de-agglomerated by RODOS module at 3 bars and when partially de-agglomerated 
as aerosolized into the INHALER module at different air flow rates (20L/min – 
100L/min). Aerosolization into the INHALER module was performed without an 
inhaler as a control, using an application device called ―Rack‖ instead of the 
inhalation device to eliminate the influence of the inhaler and gives a laminar flow for 
the particles. Hence, this would measure the aerosolization performance depending 
only on the physical nature of the powder particles. Briefly, the ―Rack‖ consists of a 
stainless steel tube with an inner diameter of 5mm and a total length of 170 mm 
shown in Figure ‎2-2. For the delivery of the powder into the air stream, powder was 
weighed into the cavity and released into the stainless steel tubing and entrained by 
the air by rotating the inner part of the applicator, and then the powder was 
discharged. 
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Figure ‎2-2: Application system "Rack" (Steckel and Bolzen 2004) 
 
For measuring the deagglomeration behavior of oseltamivir phosphate 
formulations prepared (OP/TR), the capsule is discharged into the INHALER laser 
diffraction module by the Unihaler (Figure ‎2-3) at 36 mbar which gives a flow of 
57L/min. Then, the particle size distribution behind the throat was calculated and 
compared to PSD at a cutoff point of 5µm when blends were fully de-agglomerated 
by RODOS module at 3 bars. All measurements were done in triplets and averages 
were calculated and presented using Sympatec Windox 5 software. 
 
Figure ‎2-3: (A) Different parts of the Unihaler, (B) Assembly and functional principle of the 
Unihaler. 
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Figure ‎2-4: Steps 1 to 4 showing the assembly of the preseperator and the throat to the 
inhalation module of the Sympatec laser diffraction system. (1 & 2) A plastic ring 
and a rubber ring are placed to have an air tight connection with the preseparator. 
(3) Connecting the preseparator. (4) Overall view before placing the inhaler. 
 
1 
2 3 
4 
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2.4.2 Next Generation Impactor 
In accordance with (United States Pharmacopeial Convention, 2014) (USP) 
chapter 601 specification on aerosols, the aerosolization performance of each 
prepared formulation was assessed by a Next Generation Impactor (Figure ‎2-5) 
(NGI, Copley Scientific, Nottingham, UK) evaluating the aerodynamic particle size 
distribution. For using capsule based inhalers, each formulation sample was 
accurately weighed into size 3 hydroxypropylmethylcellulose capsules (HPMC, Quali-
V® caps, SA, Spain). OP blends’ samples were in (15 ± 0.1 mg) filled capsules, while 
BU, SS, and DSCG blends’ samples were in (5 ± 0.1 mg) filled capsules. Prior to 
testing, NGI preseperator and tray cups were coated with a solution of 
Brij35:Ethanol:Glycerol at weight ratio of 15:51:34, respectively, to prevent powder 
particles from bouncing. For each experimental run, one capsule of the tested 
formulation was aerosolized and discharged into the NGI.  Afterwards, the NGI 
apparatus is dismantled and the inhaler, the throat, the preseperator and tray cups 
were washed down with known volumes of the suitable solvent. The amount of drug 
deposited in each part is calculated by either HPLC or spectrophotometric assay. The 
method was repeated three times for each formulation in an environmental controlled 
chamber at relative humidity (RH) around 40% and temperature below 25ºC. Copley 
software was used to calculate the emitted dose, the fine particle dose (FPD), the 
fine particle fraction (FPF) and the mass median aerodynamic diameter (MMAD).  
 
Figure ‎2-5: NGI closed (Left) and opened (right) schematic diagram 
  
Throat 
Preseperator 
Tray Cups 
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2.5  Drug assay 
2.5.1 UV-spectrophotometric quantification  
UV-spectrophotometric analysis was used to quantify OP at a wavelength of 
240nm. Before all quantifications, control and calibration were evaluated in terms of 
linearity, assay precision, and accuracy by different concentrations of pure OP and 
OP in combination with trehalose. Trehalose had no significant absorbance at 
240nm, and OP solutions were prepared by bi-distilled water; accordingly the 
quantification of OP was simple and sensitive for the tested concentrations. 
2.5.2 Liquid Chromatography quantification 
HPLC system (Agilent Technologies - Hewlett-Packard, Waldbronn, Germany) 
was used to quantify samples of BU, SS, and DSCG. The data was obtained and 
evaluated by LC/MS Chemstation software (Agilent Technologies, Germany). 
2.5.2.1 Budesonide (BU) 
Stationary Phase LioChroCart® 125-4 
LiChrospher® 100 RP-18 (5µm) 
With pre-column 
Mobile Phase 75% Methanol 
25% Water 
Flow Rate 1 ml/min 
Detection Wavelength 248nm 
Injection Volume 100 µl 
Calibrated Range 1 – 100 µg/ml 
 
2.5.2.2  Salbutamol Sulphate (SS) 
Stationary Phase LioChroCart® 125-4 
LiChrospher® 100 RP-18 (5µm) 
With pre-column 
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Mobile Phase 85% Buffer (3.45g Sodium dihydrogen phophate in 1L of 
0.05% triethylamine aqueous solution); pH adjusted to 
3.0 with H3PO4 (10% solution) 
15% Methanol 
Flow Rate 1 ml/min 
Detection Wavelength 224nm 
Injection Volume 50 µl 
Calibrated Range 1 – 100 µg/ml 
 
2.5.2.3  Di-sodium cromoglycate (DSCG) 
Stationary Phase LioChroCart® 125-4 
LiChrospher® 100 RP-18 (5µm) 
With pre-column 
Mobile Phase 60% Buffer (8.95g disodium hydrogen phosphate + 3.4g 
potassium dihydrogen phosphate in 1L Bidistilled water); 
pH adjusted to 3.3 by H3PO4 (10% solution) 
40% Methanol 
Flow Rate 0.8 ml/min 
Detection Wavelength 326nm 
Injection Volume 100 µl 
Calibrated Range 1 – 100 µg/ml 
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3.1 Introduction 
Oseltamivir phosphate is the leading drug in the class of oral neuraminidase 
inhibitors (NAIs) which are the primary treatment option for influenza, and can also be 
used to limit the spread of infection in close proximity environments. OP is available 
only to be administered orally (Tamiflu™; Roche Laboratories, Nutley, NJ).  
Oseltamivir is a sialic acid analogue that competitively and reversibly inhibits the 
neuraminidase enzymatic active site specific for influenza virus A and B (Dreitlein et 
al., 2001, Englund, 2002, 2002; Oxford and Lambkin, 1998). It breaks the replication 
cycle when given during the start of infection at the virus highest activity (Gillissen 
and Höffken, 2002). Oseltamivir is effective against all avian and human influenza 
strains, including the highly pathogenic H5N1 strain.  
Orally administered Oseltamivir Phosphate is a prodrug that is absorbed from 
the gastrointestinal tract with an absolute bioavailability of 75% - 80%. Then it is 
metabolized by the hepatic Carboxylesterase-1 family (CES1) into its active 
metabolite ―Oseltamivir Carboxylate‖ as shown in figure 3-1 and not metabolized by 
the intestinal tissue or the plasma esterase’s (Hosokawa, 2008; Oo et al., 2003; Shi 
et al., 2006; Zhu and Markowitz, 2009).  In adults, the standard oseltamivir treatment 
regimen is 75 mg twice daily for 5 days (Lindemann et al., 2010). 
 
Figure ‎3-1: Bioconversion of Oseltamivir into Oseltamivir Carboxylate (Eisenberg, 2007). 
 Case reports indicate that standard doses of Oseltamivir can improve 
therapeutic outcomes and survival when initiated early in the infection cycle (Clercq, 
2006). The use of higher doses of Oseltamivir drew attention for the treatment of 
avian influenza stains as the highly pathogenic H5N1. Furthermore, it was 
recommended by the World Health Organization (WHO) to treat patients with 150mg 
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twice daily. A treatment duration of 10 days was shown to be beneficial for infected 
patients (Dutkowski et al., 2010).  Oseltamivir inhalative administration is therefore be 
considered as targeting the virus at the site of the infection instead of systemic 
administration of the drug, similar to aerosolized zanamivir that is another NAI and 
topically administered as a DPI with a daily dose up to 20mg (Beigel and Bray, 2008). 
One blister dose from Relenza® contains 5mg of zanamivir formulated with 20mg 
lactose monohydrate carrier (Claus et al., 2014). The lung which is the site of direct 
administration is rich with CES 1 enzyme (Hosokawa, 2008); accordingly the drug 
can be activated at the site of action. Subsequently, delivering oseltamivir directly into 
the lung by inhalation would lower the dose, lower the oral side effects (e.g.: nausea 
and vomiting) and give direct faster activity. 
Previously, the feasibility of oseltamivir phosphate aerosolization was 
achieved using trehalose based DPI formulations with excellent indication of its 
safety on the lung cells. Besides, the study validated the high efficiency of the newly 
developed capsule-based inhaler (UNI-Haler) in dispersing highly agglomerated 
blends and its usefulness in aerosolizing oseltamivir phosphate was demonstrated 
(Aziz, 2011). 
In this study chapter, three main targets were set;  
1. To achieve an oseltamivir DPI formula with higher efficiency and better 
aerosolization performance using UNI-Haler for sustained comparison. 
2. To take a further step showing the physicochemical characterization in relation to 
the aerosolization behavior of micronized grade trehalose dihydrate as a carrier in 
oseltamivir phosphate DPI formulations. 
3. To evaluate the feasibility of bringing high drug doses into the lungs using 
trehalose as a fine carrier. 
The main study design was set to use fine trehalose carrier instead of the 
commonly used particle size range of (40µm to 200µm). Also the design added into 
consideration the effect of small particle variation (≥5µm) of the API itself.  
Based on a Design of Experiment (DOE), different micronized (D50 = 1.7 µm, 2.4 
µm and 4.8 µm) grade trehalose were investigated to optimize the fine particle 
fraction of inhaled oseltamivir in high dose blends (75% w/w). Furthermore, two OP 
particle size grades (D50 = 1.65 µm and 1.88 µm) were tested during the study to 
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measure the significance of small particle size changes on aerosol performance. 
Laser diffraction was used to evaluate the particle size distribution of jet milled 
trehalose and OP grades. Thermal behavior and crystalline structure were examined 
by differential scanning calorimetry, thermogravimetric analysis and X-ray powder 
diffraction. Likewise, micronized OP was tested for physical stability after mechanical 
milling by XRPD and DSC. Water sorption characteristics of trehalose were analyzed 
based on milled particles at different size grades. Moreover, specific surface area 
and the fluidization energy for the trehalose particles were correlated to the different 
size grade production by jet milling.  
Subsequently, blends were prepared using a turbula mixer and de-
agglomeration behavior was screened for all primary blends using laser diffraction. In 
view of that, aerosolization performance was evaluated for potential formulations 
utilizing inertial impaction. At the end of this chapter methodology, scanning electron 
microscopy visualized and evaluated the morphology of the particles in the blends to 
correlate its aerosolization performance. 
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3.2 Results 
3.2.1 Prepared jet milled particles  
From the factorial design (D-optimal charts refer to appendix), three trehalose 
batches (TR5, TR10, TR1010) were chosen based on relatively large, medium and 
small particle size diameter. The 4th (TR66) batch was chosen to compare similar 
particle size reached by different grinding conditions in terms of physicochemical 
properties. Four different batches of jet milled trehalose were successfully produced 
at different grinding conditions, evaluated and recorded (as shown in Table ‎3-1) for 
particle size distribution by laser diffraction, fluidization energy by FT4, and specific 
surface area by gas sorption analyzer. 
Table ‎3-1: Particle size distribution, fluidization energy and specific surface area for jet milled 
trehalose batches (n=3) 
 Trehalose 
batch 
Grinding 
condition 
Particle size distribution (µm) 
Fluidization 
energy (mJ) 
Specific 
surface area 
(m2/gram) 
Run 1 Run 2 D10 D50 D90 
Span 
Value 
TR5 5 bar _____ 0.9 4.8 21 4.2 51 1.25 
TR10 10 bar _____ 0.7 2.4 7 2.65 103 2.36 
TR66 6 bar 6 bar 0.6 2.4 7.3 2.67 94 2.49 
TR1010 10 bar 10 bar 0.6 1.7 4 2 134 2.73 
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On the other hand OP was only jet milled into two grades as shown in Table 
‎3-2; both are fine particles (D50 ≤ 5µm) to target possible deepest lung dispersion. 
Table ‎3-2: Particle size distribution of jet milled OP grades 
Oseltamivir 
phosphate batch 
Grinding condition Particle size distribution (µm) 
Run 1 Run 2 D10 D50 D90 Span Value 
OP10 10 _____ 0.69 1.88 7.7 3.7 
OP1010 10 10 0.67 1.65 5.1 2.7 
 
3.2.2 Physicochemical characteristics 
3.2.2.1 Thermal Behavior 
DSC scans obtained, showed typical endothermic and exothermic events for 
trehalose dihydrate at both low (5ºC min-1, 10ºC min-1) and high (100ºC min-1) 
scanning rates (Figure ‎3-2). The first endothermic peak appeared around 100ºC is 
related to the dehydration of the α-trehalose crystals (Tα). The second endothermic 
peak proceeded with an exothermic event was recorded around 120ºC and according 
to literature it is correlated to the melting of (Tα) and the formation of polymorph β-
trehalose crystals (Tβ). The last endothermic peak at about 200ºC indicates the 
melting of the more stable polymorph β-trehalose crystals (Jones et al., 2006; 
Sussich and Cesàro, 2008; Verhoeven et al., 2012). This study was made to evaluate 
the effect of micronization on such thermal behavior. At high scan rate, the finer the 
trehalose particles, the sharper the peaks. Furthermore, it was clear that decreasing 
trehalose particle size lead to a moderately faster dehydration process at lower 
temperatures as presented in Figure ‎3-3. As for the other thermal events 
melting/transition of Tα to Tβ, and melting of Tβ; they were less affected by the 
particle size reduction as illustrated in Table ‎3-3. 
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TR 16400   
   
TR5   
   
TR66   
   
TR1010   
   
Figure ‎3-2: DSC thermograms at 5ºC min
-1
 (Left side) at 10ºC min
-1
 (Middle) and 100ºC min
-1
 
(Right side) for different Trehalose batches 
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Table ‎3-3: Summary of transition temperatures at different scanning rate for milled trehalose 
grades compared to unprocessed trehalose (TR16400). 
 
 
Figure ‎3-3: Onset of dehydration temperatures for Tα crystals relative to the trehalose grade 
(particle size) 
Thermo-gravimetric analysis presented in Figure ‎3-4 confirms previous 
observation, where both samples (largest and finest trehalose particles) lost about 
9% water by weight. The dehydration started at 80 ºC, but a faster loss of weight of 
finer TR1010 (ending at ≈120°C) when compared to unprocessed TR16400 (ending 
at ≈160°C). Mechanical processing as micronization into finer particle size did not 
remove the water content but facilitated the ease of water removal when exposed to 
thermal energy. 
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TR 16400 95 95 102 113 117 129 182 186 202 
TR5 95 92 98 119 126 126 179 206 207 
TR66 94 91 98 ____ 120 127 201 202 210 
TR1010 92 87 98 ____ 130 127 204 206 209 
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Figure ‎3-4: TGA of (A) TR16400 and (B) TR1010 showing the percent weight loss (Y-axis) with 
increasing temperature °C (X-axis). 
3.2.2.2  Dynamic Vapor Sorption 
Analysis of the vapor sorption characteristics of three micronized particle 
grades trehalose dihydrate compared to the unprocessed form (TR16400) are shown 
in Figure ‎3-5. In general, trehalose dihydrate accepts water moisture to be adsorbed 
at ≥15% until it is steady at about 45% RH till 85% RH. As expected, the finer the 
trehalose particles the extra moisture it adsorbs to its surface. Observing at 50% RH, 
water sorption to TR5 (D90= 21µm) was four times more than its sorption to the 
unprocessed sample (TR16400) with change of mass of about 2%. Furthermore, at 
50% RH the change in mass of the finer trehalose TR1010 & TR66 was 2.6% & 3% 
respectively. Unexpectedly, TR1010 the finest micronized trehalose particles (D90= 
4µm) showed a lower moisture sorption than TR66 (D90= 7.3µm). This can be 
explained by the high cohesive forces between the trehalose particles that might 
have limited any further water sorption. 
 
Figure ‎3-5: DVS profile of different micronized particle grade trehalose dihydrate. 
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3.2.2.3  Crystalline structure  
XRPD spectra obtained for trehalose dihydrate before and after micronization 
shown in Figure ‎3-6 are clearly similar to those in literature (Jones et al., 2006; 
Sussich et al., 1998). This confirms the preserved structure of the trehalose dihydrate 
crystal even after micronization. Micronizing the trehalose particles into fines did not 
change the peaks detected, but only reduced their detected intensity where the finest 
particles (TR1010) gave the lowest detected intensity.  
 
Figure ‎3-6: XRPD spectra of trehalose dihydrate before micronization (TR16400) and after 
micronization (TR5 and TR1010). 
3.2.2.4 De-agglomeration behavior 
From the de-agglomeration behavior of micronized trehalose dihydrate 
presented in Figure ‎3-7; (TR5) the least fine particles showed the highest de-
agglomeration when aerosolized at different airflow rates. Furthermore, TR10 and 
TR66 having similar PSD, had similar de-agglomeration behavior as shown. 
Accordingly, in jet milling conditions, using either one or two micronization runs to 
reach similar PSD, did not affect the de-agglomeration behavior. 
 
Figure ‎3-7: Percent De-agglomeration of tested trehalose grades under different airflow rates. 
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3.2.2.5 Oseltamivir physical stability   
     By jet milling under highest 
pressure for 2 runs, the OP 
particles kept its thermal 
behavior constant. From the 
unprocessed (OP) to the finest 
particles (OP1010) , a small 
increase by less than 1°C of the 
only endothermic peak was 
observed as in Figure ‎3-8 This 
indicates a minor change in the 
amorphous part or the limited 
occurrence of impurities. 
     Furthermore, by observing 
XRPD spectra in Figure  3-9, 
there is no change in the 
crystalline pattern for both fine 
jet milled OP1010 compared to 
unprocessed OP. 
 
 
 
              Figure ‎3-8: DSC thermograms of OP grades 
 
Figure ‎3-9: XRPD spectra for OP and OP1010  
OP - unprocessed 
OP10 
OP1010 
OP1010 
OP 
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3.2.3 Blends and homogeneity 
From jet milling, three particle size grades of trehalose and two grades of 
oseltamivir were produced; accordingly six homogenous blends were prepared as 
shown in Table ‎3-4. All DPI blends prepared were considered homogenous as their 
relative standard deviation (RSD) was below 6% (Jones et al., 2010). 
Table ‎3-4: Prepared OP/TR formulations showing RSD% for UV-absorbance and OP 
concentration. 
# Blend Top Mid Bottom Mean RSD% 
1 OP10/TR5 Conc. (mg/ml) 0.21 0.21 0.22 0.21 2.71 
2 OP10/TR66 Conc. (mg/ml) 0.22 0.22 0.22 0.22 0.00 
3 OP10/TR1010 Conc. (mg/ml) 0.20 0.21 0.21 0.21 2.79 
4 OP1010/TR5 Conc. (mg/ml) 0.20 0.20 0.21 0.20 2.84 
5 OP1010/TR66 Conc. (mg/ml) 0.20 0.20 0.21 0.20 2.84 
6 OP1010/TR1010 Conc. (mg/ml) 0.20 0.22 0.21 0.21 4.76 
 
3.2.4 Aerosolization performance 
3.2.4.1 Laser diffraction 
In the second part of the de-agglomeration analysis by laser diffraction, 
OP/TR-formulations were tested at the same airflow as it would be aerosolized by 
UNI-haler in the cascade impaction at 4 kPa pressure drop across the device. Figure 
‎3-10 shows how close it would be to the Rodos module full de-agglomeration when 
using the UNI-haler depending on different PSD. Trehalose particles (TR5) that are 
about 4-5 times larger than the OP1010 PSD, gave the highest de-agglomeration 
percentage of about 98%. This indicates the highest potential of using TR5 to give 
the best aerosolization of finest OP. 
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Figure ‎3-10: Average percent de-agglomeration of all OP blends prepared at airflow 57L/min 
using the UNI-Haler (n=3). 
3.2.4.2 Cascade impaction 
For all six DPI formulations with high drug load (75%) of 15mg ± 0.1 mg filled 
capsules, the aerosolization performance at 4 kPa pressure drop was observed with 
excellent results (≥60% FPF) as shown in Figure ‎3-11. It was observed that 
formulations with OP1010 showed slightly higher FPF% than their counter using the 
less fine OP10. (OP1010/TR5) and (OP1010/TR1010) gave similar highest FPF 
values of 66% and 67% respectively.  
On the other hand, only the fine drug binding larger carrier in (OP1010/TR5) 
gave most reproducible results with FPD of 8.2mg as shown in Figure ‎3-12. While the 
interaction of the fine drug with a similar sized carrier gave slightly higher FPF% and 
similar FPD of 8.2mg, it also showed higher capsule retention and larger MMAD as 
shown in Figure ‎3-13. The formulation (OP1010/TR5) using trehalose as an inert 
carrier with a particle size range 4-5 times larger than the fine OP; gave the most 
reproducible FPF% and FPD values with lowest MMAD of 1.4µm. 
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Figure ‎3-11: Average FPF% ± SD of aerosolized OP/TR formulations using UNI-Haler @ 57L/min 
(n=3). 
 
Figure ‎3-12: Average FPD ± SD (mg) of aerosolized OP/TR formulations using UNI-Haler @ 
57L/min (n=3). 
 
Figure ‎3-13: Average MMAD ± SD (µm) of aerosolized OP/TR formulations using UNI-Haler @ 
57L/min (n=3). 
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Analysis of the aerosolization performance of the OP/TR formulations at 
higher flow rate was done with the low resistance inhaler Aerolizer®. Four blends 
were chosen to be tested that included either finest trehalose carrier or finest OP. As 
shown in Figure ‎3-14, again all blends showed excellent dispersion with FPF ≥60%. 
Aerosolization at 100L/min showed a different trend from that at 57L/min, where we 
can say that; the finest the total particles, the higher the FPF%. OP1010/TR1010 
showed highest and reproducible FPF of 75%. Compared to the lower flow rate of 
57L/min, the FPF has increased for all tested blends by 2-10% with better 
reproducibility and higher FPD values as shown in Figure ‎3-15. On the other hand, 
the MMAD values shown in Figure ‎3-16 were similar to previously aerosolized at 
57L/min, with lowest value for (OP1010/TR5) of 1.4µm. In general, the smaller the 
MMAD the more effective de-agglomeration has occurred, releasing OP closer to its 
average particle size distribution. Nevertheless, all the tested formulations showed 
similar effective de-agglomeration process as read MMAD ≤ 2 µm under both high 
and medium flow rate. This further proves the consistent efficiency of the prepared 
formulations in aerosol generation under different airflows. 
 
Figure ‎3-14: Average FPF% ± SD of aerosolized OP/TR formulations using Aerolizer @ 
100L/min (n=3). 
 
Figure ‎3-15: Average FPD ± SD (mg) of aerosolized OP/TR formulations using Aerolizer @ 
100L/min (n=3). 
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Figure ‎3-16: Average MMAD ± SD (µm) of aerosolized OP/TR formulations using Aerolizer @ 
100L/min (n=3). 
Figure ‎3-17 and Figure ‎3-18 show OP1010 particle deposition profiles from 
TR5 carrier on each NGI stage at air flow = 57 L/min and 100 L/min respectively. As 
indicated in the 57 L/min profile using the Unihaler, the finest jet milled OP1010 
exhibited low particle deposition on stage 1 (cutoff diameter point of 8.06 µm) and 
high particle deposition on stages number 4–6 reaching its maximum of about 2.7mg 
on stage number 5 (cutoff point of 0.94 µm). However, compared with the 100 L/min 
profile using the Aerolizer, the particles exhibited slightly higher particle deposition on 
stage 1 and high particle deposition on stages number 3–5 reaching its maximum of 
about 2.4mg on stage number 4 (cutoff point of 1.66 µm). Although, the particles 
were deposited deeper at 57 L/min relative to the deposition profile at 100L/min, yet 
the inhaler entrapment for particles was higher about 7.5% from the total dose. 
 
Figure ‎3-17: OP1010/TR5 - Stage distribution by Unihaler @ 57L/min (n=3) 
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Figure ‎3-18: OP1010/TR5 - Stage distribution by Aerolizer @ 100L/min (n=3) 
3.2.5 Scanning electron microscopy 
Trehalose particle morphology of largest (TR-5) and smallest (TR-1010) PSD 
were presented by SEM images under different magnification powers as listed in 
Figure ‎3-19. Both qualities were captured in pure and blend formulations with 
OP1010. As observed jet milled trehalose qualities were of irregular shape while the 
OP1010 gave rod shaped morphology. When the relatively cohesive OP1010 
particles are blended with TR-5, the rod shaped particles are totally covering and 
rounding larger particles of trehalose in a separate agglomerated pattern. However, 
when the OP1010 rod particles are in formulation with the fine TR1010, a more one 
phase agglomerated rods with the irregular trehalose particles imbedded within are 
observed. 
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Jet milled Trehalose: TR1010 
  
Blend: OP1010 / TR5 
  
Blend :OP1010 / TR1010 
 
  
Figure ‎3-19: SEM images of jet milled trehalsoe qualities (TR5 and TR1010) and in OP1010 
blends under magnification power 1KX (left) and 5KX (right).  
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3.3 Discussion 
This study chapter clearly demonstrated that trehalose micro-particulates 
produced by jet milling were successfully able to aerosolize oseltamivir phosphate 
with excellent results. Different batches were produced by jet milling based on the 
particle size distribution of both trehalose carrier and OP particles. Focusing on the 
physicochemical analysis, there was no significant change observed in crystalline 
structure, water sorption or thermo-gravimetrical behaviors that would dramatically 
alter the aerosolization behavior. On the other hand, the larger the particle size the 
less the specific surface area lowering the fluidization energy required for easier 
flowability. Furthermore, where TR10 behaved similarly to TR66, no significant 
differences observed In terms of the physical characteristics of particles with similar 
size distribution produced by jet milling but at different number of runs under different 
grinding pressure.  
The crystalline irregular particles of trehalose with a fine size range were able 
to give optimum physicochemical interaction in the binary formulations with OP finest 
particles under the studied conditions for the drug to be aerosolized efficiently. The 
studied trehalose particles (TR-5) and (TR-1010), was able to disperse and 
aerosolize OP1010 with the highest recorded FPF% under both high and medium 
flow rates. On the other hand, trehalose grade with widest particles size span (TR-5) 
showed more consistent and highest performance at the medium flow rate. While at 
the high flow rate, TR-1010 with the smallest PSD and span value showed the most 
reproducible highest performance. This can mean that, fine trehalose carrier micro-
particulates in binary formulations of high drug load may perform best with low 
resistant inhalers yet they de-agglomerate formulations’ drug particles with similar 
effectiveness under medium resistance.  
Particle surface properties have an influential role in the performance variation 
between different produced batches. In general, jet milling lead to surface 
heterogeneity of particles implying a non-homogenous energy distribution and 
morphology. Two strategies regarding the de-agglomeration behavior of the particles 
can be concluded from the results of this study. First, active sites with high energy 
have higher preference to bind strongly with the API small particles than the surface 
sites with lower energy. Accordingly for the high OP dose formulation evaluated, the 
few high energy active sites of the fine trehalose particles would be saturated easily 
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and the majority of the OP particles are binding relatively loose to the less energetic 
surface sites leading to lower adhesion and easier de-agglomeration. Secondly, 
irregular shaped particles or rough particles with asperities may lead to strong 
binding between particles by mechanical interlocking or it may limit the closeness of 
two particles and reduce the Van der Waals forces. It can be assumed that the 
irregular shaped fine particles of the trehalose reduced both the mechanical 
interlocking and the Van der Waals forces by being placed into the higher ratio of the 
fine rod shaped OP particles. This would be achieved by introducing air space in 
between the particles that facilitate the de-agglomeration process upon 
aerosolization.       
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4. Chapter Two 
Trehalose particle engineering by 
spray drying 
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4.1 Introduction 
As discussed earlier in DPI formulations, reduced inter-particulate interactions 
can lead to better aerosolization and dispersion. For that reason, spray dried particles 
with spherical morphology, narrow micron size range distribution and relatively 
smooth surface might reduce mechanical interlocking, van der Waals, and 
electrostatic forces. Spray drying is an established technique that is well described 
and studied in optimizing particle physical properties by plentiful literature. In 
pharmaceutical industry, the versatile input factors of the method enabled the 
production of engineered dry particles suitable for parenteral, nasal, and pulmonary 
delivery (Vehring et al., 2007; Vicente et al., 2013). In general spray drying 
techniques are composed of three sequential steps; atomization, droplet drying and 
particle collection. As represented in schematic diagram Figure ‎4-1, initially, the 
target particles are in solution or suspension pumped through feeding nozzle to be 
dispersed via flow of carrier gas as droplets in the drying chamber. The droplet size 
formed is the limiting factor for the particles size to be produced. Then the dispersed 
droplets undergo evaporation and solute condensation depending on the drying 
temperature and time. Afterwards, the dry particles are collected by a cyclone 
(Nandiyanto and Okuyama, 2011; Yang et al., 2014). Spray drying parameters such 
as solids concentration, solvent type, feeding rate, inlet/outlet temperatures, and flow 
rate can be optimized to target a specific physical property of the produced particles 
(Li et al., 2014; Vicente et al., 2013). 
 
 
 
 
 
 
 
 
Sample 
Solution 
Pump 
Feeding Nozzle 
Drying Chamber 
Cyclone 
Collecting vessel 
Figure ‎4-1: Spray drying process schematic diagram 
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Inhalable trehalose microparticles have been previously produced and 
examined under different parameters, but mainly to reach a potential stabilizing 
excipient with bio therapeutic drugs as proteins and peptides. These studies mainly 
targeted spray dried amorphous micropaticulate trehalose via dilute organic solutions 
(Li and Mansour, 2011; Ogáin et al., 2011). 
The purpose of this chapter is the production of smooth spherical trehalose 
particles by spray drying via aqueous solution with relatively large particle sizes and 
the study of their thermal and crystalline characteristics. The study design considered 
trehalose particles that would be suitable as a DPI formulation carrier, where the 
produced size would be in a similar range as the jet milled quality that showed 
successful aerosolization behavior in the previous study chapter for later comparison. 
Based on a design of experiment, four spray drying parameters were tested in 
controlling particle size and yield; feed concentration, inlet temperature (Tin), pump 
rate, and gas flow. The produced particles were then dispersed under 3bar with 
Rodos module for PSD analysis by laser diffraction. Afterwards, X-ray powder 
diffraction revealed the absence of crystallinity of trehalose particles after spray 
drying and vapor sorption behavior of the particles was tested under different cycles 
of RH% by DVS. Consequently, recrystallization trial of a spray dried amorphous 
trehalose sample was done at 55% RH to target spherical crystalline particles. 
Moreover, thermal behavior and detection of glass transition of the amorphous 
particles were examined by modulated-DSC. Lastly in this chapter, particle 
morphology and surface were imaged and examined by scanning electron 
microscopy. 
 
.  
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4.2 Results 
4.2.1 Spray dried Produced trehalose 
First experimental design, took into consideration four factors each with 3 
levels; Feed concentration (10, 25 and 40%w/v), T-inlet (75, 85 and 95°C), Pump 
rate (10, 15, and 20%) and Gas flow (30, 40 and 50mm). However due to 
environmental conditions of high relative humidity (80-90%), some runs with low Tin, 
high pump rate and their interaction, lead to insufficient drying process (sticky 
product) and yield of less than 10%. Accordingly, such products were not possible to 
analyze their PSD and the design calculation was incomplete. In a second 
experimental design trial, Tin was set at 95°C and the pump rate was set at 10%. It 
was observed that feed concentration and gas flow were the most significant 
parameters affecting the particle size and both tested over 3 levels as previous 
without affecting the drying efficiency. From the graphical presentation in (Figure ‎4-2) 
and statistical calculation, the particle size of the spray dried trehalose was 
significantly affected by gas flow, feed concentration, and their interaction. The 
summary statistics presented, shows two parameters; the model fit (R2) and the 
future prediction precision (Q2). Both parameters were near perfect model value of 1 
with difference between them of less than 20%. In general, increasing the feed 
concentration, results in more solid in the dispersed droplets leading to larger 
particles. While, increasing the gas flow, results in more dispersed smaller droplets 
leading to smaller particle upon drying. 
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Figure ‎4-2: DOE graphs presenting coefficients significantly affecting SD trehalose PSD 
outcome of D10, D50 and D90 with excellent model fit and precision (R2>0.9 & Q2≥0.75); on the 
X-axis (A) Concentration, (B) Gas flow and (B-B) Gas flow – Gas flow interaction, while the Y-
axis shows the change in µm.  
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For further physicochemical analysis, three batches were chosen based on 
particle size distribution as shown in Table  4-1. 
Table ‎4-1: Spray dried three trehalose batches of relatively small, medium and large PSD 
Sample 
Name 
Feed 
Conc. 
%(w/v) 
T-inlet 
(°C) 
Pump 
rate (%) 
Gas flow 
(mm) 
PSD (µm) 
d10 d50 d90 
Span 
value 
L-4913 40 95 10 30 1.78 9.05 19.64 1.97 
M-2914 25 95 10 40 0.80 4.11 9.47 2.1 
S-1915 10 95 10 50 0.62 2.25 5.57 2.2 
 
4.2.2 X-ray powder diffraction  
Under spray drying conditions for the three chosen batches, it was confirmed 
as seen by the XRPD pattern (Figure ‎4-3), that trehalose lost its crystalline structure. 
Initially, trehalose dihydrate gave its default intense sharp peaks as seen previously 
in chapter one. The drying process was sufficient to remove water molecules in 
solution droplets before the formation of any crystal lattice leaving solid dry 
amorphous trehalose particles in all three batches. 
 
 
 
 
 
 
 
Figure ‎4-3: XRPD spectra of SD trehalose and raw trehalose dihydrate. 
Trehalose dihydrate 
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4.2.3 Dynamic Vapor Sorption 
The vapor sorption profile in Figure ‎4-4 illustrates the capacity of the 
amorphous trehalose particles to water molecules in a cycle up to 70% RH. Raw 
trehalose dihydrate particles can only adsorb water molecules of less than 1% from 
its mass. On the other hand spray drying producing amorphous trehalose particles, 
lead to increased water adsorption capacity of about 10 times at RH ≥ 50%. The TR-
SD particles showed constant increase in water sorption as soon as the RH is above 
0% till reaching plateau at 50% RH. Comparing the water sorption profile of the three 
TRSD batches (small, medium and large); a slight variation is observed where the 
larger the particle size distribution the less water capacity. 
 
Figure ‎4-4: DVS profile of spray dried trehalose batches and trehalose dihydrate (TR - Raw) 
4.2.4 Scanning electron microscopy   
The SEM images of all three spray dried trehalose batches are displayed in 
Figure ‎4-5. The magnification power showing the smallest particle sized batch (S-
1915) was 1K X and 5K X, the medium particle sized batch (M-2914) was shown 
under 1.5K X and 5K X, while the large particle sized batch was shown under 1KX 
and 2.5K X. It was clearly obvious the successful production of smooth spherical 
particles for all batches. However, larger particles tend to have a less smooth surface 
as seen specifically in L-4913 sample. 
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TRSD (S-1915) 
 
TRSD (M-2914) 
 
TRSD (L-4913) 
 
Figure ‎4-5: SEM images of spray dried trehalose (TRSD) batches. 
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4.2.5 Recrystallization of spray dried trehalose 
In target of crystalline spherical trehalose particles, recrystallization of 
amorphous spherical spray dried trehalose trial was conducted. TRSD (M-2914) was 
conditioned in room temperature at 50% RH for 24hrs. Particle size distribution and 
modulated differential scanning calorimetric measurements were recorded every 2hr 
interval as illustrated in Table ‎4-2. The initial produced powder of trehalose particles 
by spray drying, as seen in Figure ‎4-6, showed amorphous glassy to rubbery phase 
transition (Tg) at around 59.7°C with no observation for the endothermic transition 
events (dehydration & melting) normal to trehalose dihydrate.  
 
Figure ‎4-6: mDSC thermogram of TRSD (M-2914) 
Conditioning the TRSD sample in 50% RH for 6hrs, was enough for the 
particles to adsorb water molecules restoring some crystallinity and preserving its 
powder form. Observing Table ‎4-2, with time during the 6hrs, the particles tend to 
increase in size and have a reduced Tg that reached 18°C. Furthermore, after 6hrs 
the appearances of endothermic peaks (dehydration and melting) are observed with 
weak intensity along with lowest Tg recorded as seen in Figure ‎4-7. Conditioning at 
50% RH for more than 6hrs, lead to the formation of sticky stone like product. 
Accordingly, particle size distribution was not possible to be measured for samples 
more the 6hrs, while the DSC results showed similar endothermic peaks (dehydration 
and melting) as the raw trehalose dihydrate and no Tg was detected. 
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Table ‎4-2: Particle size distribution, glass transition onset and dehydration peak recorded at 
different time intervals for TRSD (M-2914) conditioned at 50%RH 
Time 
(hr.) 
Particle Size Distribution (µm) Glass transition 
onset (Tg) °C 
Dehydration 
Peak (Tε) °C D10 D50 D90 
Span 
Value 
0 0.81 4.11 9.85 2.2 52.7 _______ 
2 0.84 4.26 10.14 2.18 38.8 _______ 
4 1.05 4.96 10.99 2.0 25.7 _______ 
6 1.52 5.91 11.97 1.77 18.2 101 
8 _______ _______ 92 
24 _______ _______ 90 
 
 
Figure ‎4-7: mDSC thermogram of TRSD (M-2914) conditioned at 50%RH for 6hrs. 
Partially crystalline spray dried trehalose particles imaged by SEM, showed 
intact smooth spheres similar to the previously examined amorphous TRSD (2914). 
As observed in Figure ‎4-8, the particles are smooth and spherical but formed bridge 
like formation in between may be due to capillary bridges by water interface. The 
fused spherical particles still preserved suitable size distribution that is slightly larger 
compared to the spray dried batch. 
 
Figure ‎4-8: SEM images of recrystallized-TRSD conditioned at 50%RH for 6hrs (REC.M-2914). 
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4.3 Discussion 
As presented in this study chapter, trehalose micro-particulates can be 
successfully produced by spray drying. Operating simple spray-drying technique with 
varying concentrations of aqueous solvent solution at different gas flows; the micro-
particulates were successfully produced with smooth spherical morphology, 
amorphous and relatively large particle size up to 20µm with narrow size distribution 
(span value range of 1-2). Furthermore, amorphous particles with lowest possible 
water content would decrease the capillary forces between particles leading to better 
de-agglomeration performance. Nevertheless, crystalline particles would possess 
more stability especially towards water moisture adsorption and degradation in high 
relative humidity. In remark to that, Relative Humidity is an indispensable factor that 
significantly affects the production process of particles by spray drying as well as the 
physical stability that can affect the results of the thermal and crystallinity 
measurements. As it was mentioned earlier, high relative humidity has limited the 
possibilities for the production of the target particles in a dry powder form. Certainly, 
the water content in the dispersed solution particles in the drying chamber 
evaporates more efficiently in a relatively dry air flow rather than saturated with moist.  
On the other hand, trehalose has different physical phases that have been studied in 
many literatures to elucidate the biological protective function against dehydration 
stress. They have also shown the transformation from one phase to another under 
thermal, dehydration and rehydration processes were humidity played an essential 
role between these transitions. 
 
Figure ‎4-9: Trehalose phase and state transition under thermal and humidity conditions 
(adapted from Furuki et al., 2005) 
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As illustrated in Figure ‎4-9, four different crystalline forms have been 
recognized and demonstrated showing the transition states under different 
conditions. In accordance to (Furuki et al., 2005), the findings from chapter one and 
two demonstrate that the transition observed by DSC occurred through the 
intermediate humidity rout that gave the anhydrate (Tε) at about 90
oC. Indeed the 
amorphous spray dried trehalose particles, showed quick rehydration behavior over 
8hrs reaching the dihydrate crystal at 50% RH in room temperature. This fast 
rehydration process can also be explained by the small particle size that has high 
surface to volume ratio accepting water molecules easier. Yet again at intermediate 
humidity of the room conditions, thermal behavior of the partially recrystallized 
trehalose particles showed similar behavior with (Tε) observed at about 90
oC. The 
partially crystallized rehydrated particles behaved as a mixture of crystalline dihydrate 
and amorphous particles were glass transition was spotted at a very low temperature 
of 18 oC by mDSC, hydration and phase transitions peaks were observed by DSC 
and the XRPD patterns showed XRPD pattern with lower intensity than the fully 
crystalline particles.     
In conclusion of this chapter, the production of smooth spherical SD trehalose 
particles was successful in the desired particle size range. The particles produced 
were amorphous particles which can be considered as an inferior option in terms of 
physical DPI carrier stability compared to the crystalline particles of trehalose. In trial 
to produce more stable crystalline particles, only partial recrystallization of the 
smooth spherical SD trehalose particles was achieved, maintaining the produced 
morphology and size range. Full crystallization of spherical smooth particles could not 
be achieved due to the formation of sticky stones like structures instead of the 
required flowing powder particles under further exposure to the crystallization 
conditions. However, the produced trehalose particles either amorphous or partially 
crystalline might have the potential as an inert carrier to effectively aerosolize DPI 
formulations. Indeed, spray dried trehalose was previously observed for its protective 
activity as a carrier for potent bio-macromolecules (Rahimpour et al., 2014), 
accordingly the produced SD trehalose particles could be of further use in such DPI 
formulations. Consequently in the coming chapter, the produced SD trehalose 
particles are to be initially tested for their performance as DPI carrier despite their 
physical stability drawback. 
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5.1 Introduction 
Each specific drug/carrier combination in formulations requires a different 
design of physiochemical properties to reach optimum aerosolization behavior. The 
idea of reaching and setting one rule that fits all is totally unrealistic. As it has been 
studied in numerous literatures, contradicting observations can be perceived each 
with argue and reason, yet they prove the idea of tailored formulations for each API. 
In some studies, elongated lactose and mannitol carrier particles with higher 
surface area relative to more spherical particles were capable to flow deeper in the 
air stream due to better aerodynamics thus improving the overall aerosolization 
performance of salbutamol sulphate. It was also reported that increasing the surface 
smoothness of the carrier particles increases the aerosolization performance of the 
API (Kaialy et al., 2010; Larhrib et al., 2003; Young et al., 2002, Zeng et al., 2000a, 
2000b).  Indeed, DPI formulations with irregular carrier shapes such as elongated, 
needle-like, or even pollen shaped particles (Hassan and Lau, 2011) have all resulted 
in increased aerosolization performance of various drugs under different 
concentrations and flow rates.  However, other studies demonstrated that spherical 
spray dried lactose and mannitol particles with rough surfaces (increased surface 
area) achieved better aerosolization performance than using irregular shaped or 
smooth particles with various drugs (Kawashima et al., 1998; Littringer et al., 2012). 
Another key factor that considerably affects the aerosolization performance is the 
carrier particle size which is also still to date not fully understood. In contrast to the 
usual carrier size (40-200µm) used in DPI formulations, several studies have found 
an increase in aerosolization performance with decreasing carrier size. Lactose 
grade with particle size ≤32µm showed the best aerosolization performance of 
budesonide using different concentrations at 4KPa pressure drop compared to larger 
particles (Kaialy et al., 2012; Steckel and Müller, 1997). Furthermore, salbutamol 
sulphate with lactose carrier (Zeng et al., 2000a), disodium cromoglycate with lactose 
and dextrose monohydrate carriers (Braun et al., 1996), also proved that smaller 
carrier particle size lead to improved aerosolization performance. It was concluded 
from these results, that smaller carrier particles had less mechanical interaction with 
the API particles that lead to the improved de-agglomeration behavior, hence better 
aerosolization performance. 
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In summary, optimized aerosol generation can be achieved; by surface 
smoothing or roughing, by formatting into irregular or spherical morphology and even 
by reduction of the carrier particle size. It all depends on the interaction either 
physically or chemically between the specific ingredients particles used in the 
formulation and the ease of flow of those particles. From here comes the necessity of 
new DPI carriers with particle engineering -specifically trehalose- with the potential to 
diversify the use of new API in DPI formulations and enhance the aerosolization 
performance for the model inhaled drugs.   
On the other hand, by studying the API particle properties and their effect on 
the aerosolization performance, it was pointed out that aerodynamic particle diameter 
for all APIs should be in the range of 1 – 5 µm for optimum performance. 
Nevertheless different API particles hold diverse surface adhesive and cohesive 
characteristics. Thus for each API, morphological engineering is required to control 
the surface interactions that would generate optimized aerosolization performance. 
API engineered particles by spray drying is not always spherical; they may have 
surface convolutions, voids, holes and asperities (Johnson, 1997) that determine the 
surface roughness. 
 Some studies on salbutamol sulphate showed better achievable 
aerosolization performance with coated smoother elongated surfaces (Raula et al., 
2009). While in another study by (Steckel and Brandes, 2004) on salbutamol 
sulphate, they produced spray dried low density porous irregular shaped particles 
with lower surface area that showed more homogenous PSD and resulted in better 
aerosolization performance than the jet milled irregularly shaped drug particles. 
Another study formulated budesonide as porous particles with a sponge-like 
morphology that was tested at both high and low flow rates with excellent 
performance (Duddu et al., 2002). The model of having a less smooth API particle 
surface was further proved by  (Chew, Nora Y K et al., 2005) when achieved a 
significant improvement in the aerosol performance of the powder as the degree of 
surface corrugation of spray dried particles increased.  
Targeting optimum performance, API in DPI also requires particle modification 
regarding morphology and surface characteristics, but the particle size distribution 
must be limited to the range of 1 – 5 µm.  
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This study chapter aimed two main objectives; 1) Aerosolization performance 
comparison between different qualities of spray dried and jet milled trehalose 
particles as an inert carrier in DPI formulations. 2) The correlation of surface 
morphology and dispersive energy to the aerosolization performance. The study 
design was based on the previously produced trehalose particles by jet milling and 
spray drying in combination with model inhaled COPD drugs that were also produced 
each as two qualities by jet milling and spray drying. Budesonide and salbutamol 
sulphate were used as model hydrophobic and hydrophilic APIs respectively. 
Additionally, the aerosolization behavior of spray dried trehalose in case of 
hygroscopic drug was evaluated using Disodium cromoglycate as the model drug in 
formulations.  
A B 
      
 
C 
 
D 
  
Figure ‎5-1:Schematic diagram of the four main binary blend categories prepared and tested for 
aerosolization performance; A) jet milled API/ jet milled trehalose, B) spray dried API / jet milled 
trehalose, C) jet milled API / spray dried trehalose, D) spray dried API / spray dried trehalose 
Blend Dispersed API 
Inhaler Device 
Blend Dispersed API 
Inhaler Device 
Blend Dispersed API 
Inhaler Device 
Blend Dispersed API 
Inhaler Device 
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In general, the binary blends prepared were of four categories as illustrated in 
Figure ‎5-1 based on the morphology of the drug and carrier particles; either irregular 
by jet milling or spherical by spray drying. In addition, each category had different 
factors tested within, based on different produced qualities/batches from the 
trehalose and the different types of API used. Thus a total of 27 blends were 
prepared, tested for homogeneity and analyzed for aerosolization performance. All 
blends were analyzed by cascade impaction using capsule based Aerolizer at 
100L/min and some were further tested by multi-dose Easyhaler at 50L/min to 
associate with the air flow effect on the aerosolization performance. The Aerolizer 
(Figure ‎5-2-A) represents the model inhaler for low resistance single dose devices. 
Prior to cascade impaction, the capsules were filled with 5mg powder loaded with 
20% drug. Additionally, Easyhaler (Figure ‎5-2-B) was the model inhaler for medium 
resistance reservoir multi-dose devices. Its storage container was also filled with 
blends containing 20% API for comparable results. In attempt to correlate the 
aerosolization performance with particle surface energy and morphology, inverse gas 
chromatography was used to measure and calculate the dispersive surface energy, 
while SEM images showed the particle surface morphology in blends.   
 
Figure ‎5-2: Schematic diagram of A) Aerolizer® and B) Easyhaler®, showing I) Pressing 
direction and II) powder flow and exit. 
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5.2 Results 
5.2.1 Choice of trehalose and API qualities 
As previously studied, micron sized trehalose particles were successfully 
produced to be tested as inert carrier for DPI formulations by two methods; spray 
drying (SD) and jet milling (JM). Accordingly from each produced quality, batches for 
aerosolization performance analysis (listed in Table ‎5-1 ) were mainly chosen based 
on the particle size distribution. The choice took into consideration relatively large (L-
4913), medium (M-2914) and small (S-1915) amorphous spray dried trehalose 
particles. Also included the medium sized in a recrystallized form (REC.M-2914) as a 
side trial for the effect of water content in trehalose particles. Furthermore, jet milled 
trehalose batches of relatively large (TR-5) and small (TR1010) crystalline particles 
were of similar particle size as the spray dried batches to compare the effect of 
particle morphology on the aerosolization performance. 
 For testing the aerosolization performance of trehalose as an inert carrier, 
trehalose was to be blended with a model inhalable drug. Besides, the trehalose 
efficiency to disperse the drug should be related to the interaction with the API’s 
physicochemical nature. Thus, budesonide, salbutamol sulphate and disodium 
cromoglycate were chosen to represent model hydrophobic, hydrophilic, and 
hygroscopic drugs respectively for analysis. In addition that all the API batches were 
in the inhalation size grade, each was of two qualities; spray dried and jet milled as 
shown in Table ‎5-2. Although, all produced API qualities had a similar aerodynamic 
particle size range, yet the morphology was divergent as investigated by SEM and 
presented in Figure ‎5-3. Spray dried budesonide (BU-SD) showed incomplete 
spheres with concave sides; while the jet milled quality (BU-JM) was of irregular 
shape with rough surface. Spray dried salbutamol sulphate (SS-SD) showed 
spherical particles with corrugated surface while the jet milled (SS-JM) particles 
showed rod shaped with smaller irregular particles. Spray dried disodium 
cromoglycate (DSCG-SD) showed convoluted brain like structure in a spherical 
format, but the jet milled (DSCG-JM) showed irregular shaped particles with scaly 
rough surface. 
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Table ‎5-1: Particle size distribution of spray dried and jet milled trehalose batches prepared for 
blending formulations. 
PSD 
Spray dried Jet milled 
L-4913 M-2914 S-1915 Rec.M-2914 TR-5 TR-1010 
D10 1.78 0.8 0.62 1.52 0.96 0.75 
D50 9.05 4.11 2.25 5.91 5.05 2.23 
D90 19.64 9.47 5.57 11.97 18.33 6.13 
Span value 1.97 2.11 2.20 1.77 3.44 2.41 
 
Table ‎5-2: Particle size distribution of spray dried and jet milled model API for formulations 
analysis. 
PSD 
Salbutamol sulphate Budesonide Di-sodium cromoglycate 
SD - SS JM - SS SD - BU JM - BU SD - DSCG JM -DSCG 
D10 0.64 0.8 0.75 0.55 0.66 0.66 
D50 2.23 2.33 1.77 1.43 2.29 2.34 
D90 5.65 5.76 3.58 4.16 5.34 5.82 
Span Value 2.25 2.13 1.60 2.52 2.04 2.21 
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BU-SD 
 
BU-JM 
 
SS-SD SS-JM 
  
DSCG-SD DSCG-JM 
  
Figure ‎5-3: SEM Images of spray dried (Left) and jet milled (Right) API particles under 10000X 
magnification power.  
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5.2.2 Blends preparation 
As described in the methodology section, blending was done mainly with a 
turbula mixer to produce 20% drug loaded formulations. As shown in Table ‎5-3, 27 
DPI blends were successfully prepared and considered homogenous as their RSD% 
was significantly below 6%. The blends prepared can be classified into three main 
groups as follows; 
A. Hydrophobic budesonide (BU-SD or BU-JM) / trehalose SD (L-4913, M-2914, S-
1915) or trehalose JM (TR-5, TR1010). 
B. Hydrophilic salbutamol sulphate (SS-SD or SS-JM) / trehalose SD (L-4913, M-
2914, S-1915, REC.M-2914) or trehalose JM (TR-5, TR1010). 
C. Hygroscopic disodium cromoglycate (DSCG-SD or DSCG-JM) / trehalose SD 
(L-4913, M-2914, S-1915). 
Table ‎5-3: Homogeneity of all binary prepared blends by turbula mixing, showing RSD% 
calculated based on average values for each top, middle, and bottom samples. 
Blend # Blend Code 
Prepared Concentration Homogeneity 
Blend Conc. 
(mg/ml) 
API Conc. 20% 
(mg/ml) 
SD RSD % 
1 BU-SD / L-4913 
0.3 mg/ml 0.06 mg/ml 
0.002 3.246 
2 BU-SD / M-2914 0.002 2.564 
3 BU-SD / S-1915 0.001 1.742 
4 BU-JM / L-4913 0.001 1.648 
5 BU-JM / M-2914 0.001 1.842 
6 BU-JM / S-1915 0.002 3.857 
7 BU-SD / TR-JM 5 
0.25 mg/ml 0.05 mg/ml 
0.002 4.416 
8 BU-SD / TR-JM 1010 0.002 3.114 
9 BU-JM / TR-JM 5 0.001 1.738 
10 BU-JM / TR-JM 1010 0.001 2.949 
 
 
Chapter Three 
68 
Table ‎5-3 continued 
11 SS-SD / L-4913 
0.3 mg/ml 0.06 mg/ml 
0.002 3.122 
12 SS-SD / M-2914 0.002 3.862 
13 SS-SD / S-1915 0.001 1.945 
14 SS-JM / L-4913 0.000 0.803 
15 SS-JM / M-2914 0.003 4.404 
16 SS-JM / S-1915 0.001 1.508 
17 SS-SD / TR-JM 5 
0.5 mg/ml 
 
0.1 mg/ml 
 
0.001 1.323 
18 SS-SD / TR-JM 1010 0.001 1.265 
19 SS-JM / TR-JM 5 0.001 1.168 
20 SS-JM / TR-JM 1010 0.004 3.974 
21 SS-JM / REC.M-2914 0.4 mg/ml 0.08 mg/ml 0.003 3.869 
22 DSCG-SD / L-4913 
0.3 mg/ml 
 
 
0.06 mg/ml 
 
 
0.001 2.113 
23 DSCG-SD / M-2914 0.001 1.593 
24 DSCG-SD / S-1915 0.002 2.477 
25 DSCG-JM / L-4913 0.000 0.706 
26 DSCG-JM / M-2914 0.001 1.263 
27 DSCG-JM / S-1915 0.001 1.337 
 
5.2.3 Aerosolization performance by NGI 
5.2.3.1 Hydrophobic Budesonide (BU) blends 
In addition to the prepared binary blends, carrier free formulations of spray 
dried (BU-SD) and jet milled (BU-JM) budesonide were also tested as a 100% control 
in 1 mg filled capsule for comparison with the 20% of 5mg blends filled capsules. As 
illustrated in the FPF% chart for the budesonide formulations (Figure ‎5-4), 
aerosolization performance was generally very good as they were all above 50%. It 
was obvious that 1 mg carrier free formulations showed highest FPF% range where 
the BU-SD released about 85 % fines and BU-JM released 76% fines. This might 
indicate that the aerosolization behavior of the spray dried quality was relatively 
better than the jet milled quality for the hydrophobic drug. After comparing the binary 
blends, the indication of better aerosolization of BU-SD than the BU-JM is further 
Chapter Three 
69 
proved with all qualities of trehalose. From these results, we can interpret that the 
physical properties of BU particles with concave sided spheres may give less 
mechanical interlocking, better flowability or better aerodynamic properties than the 
irregularly shaped rough particles. 
In the next observation, the difference in the PSD of spray dried trehalose, 
slightly affected the performance of the BU-SD dispersion (72% – 78% FPF), while it 
had a greater effect on the BU-JM dispersion. The Largest SD trehalose PSD (L-
4913) gave best performance with BU-JM by 68% FPF, while the smallest SD 
trehalose PSD (S-1915) showed the lowest dispersion efficiency of BU-JM with FPF 
of 52%. On the other hand, the smallest jet milled quality of trehalose (TR-1010) 
showed slightly better aerosolization performance than the larger (TR-5) when tested 
with both BU-SD and BU-JM. Through the whole chart, the highest achieved FPF% 
was about 81% with the binary blend (BU-SD / TR-1010) and 85 % by the carrier free 
(BU-SD). 
 
Figure ‎5-4: FPF% chart for Budesonide with different Trehalose batches and carrier free 
formulations, aerosolized at 100L/min by Aerolizer (n=3 ±SD). 
Changing focus to the FPD chart (Figure ‎5-5), (BU-SD / TR-1010) was able to 
deliver the highest amount (750µg) of fine BU-SD, even more than the carrier free 
form that delivered 660µg. This indicates that, finest trehalose carrier (TR-1010) was 
able to release BU-SD and disperse it from the most efficient formulation with least 
capsule retention. From this point, it was concluded that using fine jet milled 
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trehalose particles as an inert carrier for BU, would be beneficial for lowering the 
adhesion to the capsule walls and gives more efficient formulations than the carrier 
free.    
 
Figure ‎5-5: FPD chart for Budesonide with different Trehalose batches and carrier free 
formulations, aerosolized at 100L/min by Aerolizer (n=3 ±SD). 
To observe the aerosolization behavior of the budesonide formulations 
containing spray dried trehalose batches only at medium flow rate, cascade 
impaction analysis took place using the Easyhaler device at 45L/min. In contrast to 
the results from the high flow rate previously observed, the formulations with BU-JM 
showed better aerosolization performance in terms of FPF% than their counter 
formulation with BU-SD as presented in Figure ‎5-6. The highest achieved FPF of BU-
JM was about 31% by both the larger trehalose particles (L-4913 & M-2914). Further 
insight on the performance of trehalose particles to disperse budesonide particles at 
the lower flow rate can be observed by the FPD chart in Figure ‎5-7.  
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Figure ‎5-6: FPF% chart for Budesonide formulations with spray dried trehalose batches, 
aerosolized at 45L/min by Easyhaler (n=3 ±SD). 
 
Figure ‎5-7: FPD chart for Budesonide formulations with spray dried trehalose batches, 
aerosolized at 45L/min by Easyhaler (n=3 ±SD). 
Despite of the overall lower dispersion efficiency, spray dried trehalose 
behaved in a similar trend compared to its aerosolization performance at high flow 
rate of 100L/min. Indeed relatively larger trehalose particles were able to disperse 
and deliver higher fine particle dose from both qualities of the budesonide, achieving 
maximum delivery of 270µg from (BU-JM / L-4913). A major problem encountered by 
using the Easyhaler at flow rate of 45L/min, was the dose uniformity reflected by the 
fluctuating standard deviation for each formulation’s runs. It was observed that the 
dose uniformity was highly affected by the handling of the inhaler while pressing to 
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load the dose. Slight shaking or tapping might have increased the amount loaded 
thus the total amount released. This observation can be correlated to the generally 
reduced flowability of the formulations fine particles. Further looking at the data from 
the NGI runs, High BU fraction on throat and preseperator suggest that the powder 
was not effectively de-agglomerated upon aerosolization under 45L/min and was 
released in the form of bulk agglomerates. These agglomerates were entrapped by 
the throat and preseperator which could not pass deeper onto the NGI stages.  
In comparison with using the Aerolizer, the capsule retention at 100L/min was 
≤3% from the total filled powder for all the formulations tested. Certainly the particles 
were effectively de-agglomerated by the Aerolizer even before leaving the capsule 
due to the high flow and further dispersed by the inhaler grid to reach deeper onto the 
NGI stages as observed earlier. 
5.2.3.2  Hydrophilic Salbutamol sulphate (SS) blends 
In addition to the prepared binary blends, carrier free formulations of spray 
dried (SS-SD) and jet milled (SS-JM) salbutamol sulphate were also tested as a 
100% control in 1 mg filled capsule for comparison with the 20% of 5mg blends filled 
capsules. As illustrated in the FPF% chart for the salbutamol sulphate (Figure ‎5-8), 
aerosolization performance showed more significant differences compared to the 
results of the hydrophobic budesonide formulations. Once more, it was obvious that 1 
mg carrier free formulations showed highest FPF% range where the SS-SD released 
about 42 % fines and SS-JM released 74% fines. Nevertheless, this indicates that the 
aerosolization behavior of the jet milled quality was significantly better than the spray 
dried quality for the hydrophilic drug unlike the hydrophobic budesonide 
aerosolization behavior. When coming to compare the binary blends, the fact of 
better aerosolization of SS-JM than the SS-SD is further proved with all qualities of 
trehalose. 
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Figure ‎5-8: FPF% chart for Salbutamol sulphate with different Trehalose batches and carrier 
free formulations, aerosolized at 100L/min by Aerolizer (n=3 ±SD). 
In the following observation, the difference in the PSD of spray dried 
amorphous trehalose particles, slightly affected the performance of the SS-SD 
dispersion (15% – 22% FPF), while it had a greater effect on the SS-JM dispersion 
(17% – 33% FPF). Furthermore, the smallest SD trehalose PSD (S-1915) gave best 
performance with SS-JM and SS-SD. while the largest SD trehalose PSD (L-4913) 
showed the lowest dispersion efficiency of SS-SD with 15% FPF and comparable 
performance to (S-1915) with SS-JM releasing 28% FPF. Unexpectedly, the medium 
sized trehalose particles M-2914 showed the lowest performance with SS-JM 
releasing only 17% FPF. However, the partially recrystallized (REC.M2914) which 
has similar PSD as (M-2914) showed the best performance compared to the spray 
dried trehalose qualities with 47% FPF. 
On the other hand, jet milled crystalline trehalose qualities in formulations, 
showed better aerosolization performance than their counterpart of amorphous spray 
dried trehalose particles. The smallest jet milled quality of trehalose (TR-1010) 
showed slightly better aerosolization performance than the larger (TR-5) when tested 
with both SS-SD and SS-JM. Through the whole chart, the highest achieved FPF% 
was about 53% with the binary blend (SS-JM / TR-1010) and 74 % by the carrier free 
(SS-JM). 
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Figure ‎5-9: FPD chart for Salbutamol sulphate with different Trehalose batches and carrier free 
formulations, aerosolized at 100L/min by Aerolizer (n=3 ±SD). 
For further insight on the aerosolization performance, Figure ‎5-9 shows the 
fine particle dose of salbutamol sulphate that was actually released and dispersed 
deep in the impactor. It is observed that particle size distribution differences within 
trehalose qualities did not have substantial effect on the performance. The jet milled 
trehalose qualities both TR-5 and TR-1010 performed similarly by releasing 370µg 
SS-JM. The spray dried trehalose (L-4913 & S-1915) also gave similar results of 
about 220 µg SS-JM. Instead, performance differences were observed depending on 
the quality of the trehalose particles to release the hydrophilic SS-JM. The 
performance order of the formulations based on the physical form of the trehalose 
carrier particles can be set as; (amorphous SD-trehalose < partially crystalline SD-
trehalose < fully crystalline JM-trehalose). This behavior can be correlated to the 
moisture content of trehalose particles, where the more the trehalose particles are 
crystalline the less the binding with the hydrophilic SS, the easier the de-
agglomeration and dispersion.    
5.2.3.3  Hygroscopic Disodium cromoglycate (DSCG) blends 
The binary blends prepared, focused to present the performance of the amorphous 
spray dried trehalose as a carrier in aerosolizing the highly hygroscopic DSCG. In 
addition to the prepared binary blends, carrier free formulations of spray dried (SS-
DSCG) and jet milled (DSCG-JM) disodium cromoglycate were also tested as a 
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100% control in 1 mg filled capsule for comparison with the 20% of 5mg blends filled 
capsules. However, DSCG-JM and DSCG-SD carrier free formulations failed to be 
discharged efficiently showing capsule retention of ≥ 60% and accordingly FPF% was 
not calculated. It was observed that, the performance of the tested formulations did 
not depend solely on the variation of the SD-trehalose particle sizes with each DSCG 
quality. Indeed, two more factors governs the performance outcome; firstly the 
hygroscopic nature of DSCG particles and their interaction with the amorphous 
trehalose particles. Secondly, the different surface morphology which was shown as 
convoluted brain like spheres for DSCG-SD and irregular particles for DSCG-JM with 
scaly rough surface.  
At start, SD-trehalose carrier was successful in efficiently discharging both 
qualities of DSCG. The relatively medium (M-2914) and large (L-4913) trehalose 
particles did release both DSCG qualities with average capsule retention of ≤3%. 
Nevertheless, the smallest PSD trehalose batch (S-1915) performed the least in 
releasing DSCG upon aerosolization. (DSCG-SD / S-1915) formulation showed 
average capsule retention of about 20%, while (DSCG-JM /S-1915) formulation 
showed average capsule retention of about 7.5% of the total capsule filled powder. 
For further analysis of the aerosolization behavior Figure ‎5-10 represents the 
performance of amorphous spray dried trehalose particles in dispersing hygroscopic 
DSCG in terms of FPF%. The largest PSD trehalose batch (L-4913) had similar 
performance aerosolizing DSCG-SD by 18% FPF and DSCG-JM by 16% FPF. On 
the other hand, the smallest PSD trehalose batch (S-1915) showed performance 
variation, where DSCG-SD was dispersed by 8% FPF and DSCG-JM by lowest 
achieved performance of 1% FPF. In general, both trehalose qualities (L-4913) and 
(S-1915) showed relatively better aerosolization behavior in terms of releasing higher 
fraction of DSCG-SD compared to DSCG-JM. Unexpectedly, the medium PSD 
trehalose batch (M-2914) showed an opposing behavior, where it gave the best 
aerosolization performance with DSCG-JM reaching 28% FPF releasing 230 µg and  
lowest performance with DSCG-SD getting 7% FPF releasing 60µg. 
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Figure ‎5-10: FPF% chart for Disodium cromoglycate with spray dried Trehalose batches, 
aerosolized at 100L/min by Aerolizer (n=3 ±SD). 
 By observing the results of the NGI stage distribution presented in Figure 
‎5-11, trehalose PSD different batches had a noticeable effect on the aerodynamic 
particle size distribution among the NGI stages. Based on the high affinity of the 
hydrophilic DSCG to bind with the hydrophilic trehalose particles, and the mechanical 
interaction of the different morphologies, strong agglomerates were formed with a 
relative variation in size. The larger trehalose particles (L-4913) formed larger 
agglomerates that were caught early in the throat, yet they can release some loose 
fines giving relatively higher DSCG fraction deeper on the NGI stages. This shows 
the least morphological influence of DSCG qualities when using the largest SD-
trehalose quality. Indeed, smaller PSD of the used trehalose particles in the 
formulations showed more profound DSCG morphological influence on the 
aerosolization behavior. The medium sized trehalose particles (M-2914) also formed 
some large agglomerates that were caught early in the throat, but not as large as the 
agglomerates formed by (L-4913). Accordingly, for the (DSCG-SD / M-2914) a higher 
fraction of the agglomerates were formed in size to be captured by the preseperator 
and not releasing much loose fines to reach deeper. Focusing on (DSCG-JM / 
M2914), also medium sized agglomerates were formed that were similarly captured 
by the throat. Nevertheless, the irregular DSCG-JM particles was most effectively 
released as fines to reach deeper and not to be captured as much by the 
preseperator, thus this formulation showed highest achieved FPF%. The smallest 
sized trehalose particles (S-1915) have showed the least particle deposition in the 
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throat for both DSCG qualities, but highest particles deposition in the preseperator. 
This can be related again to the size of the agglomerates that were able to pass the 
throat but not the preseperator. Besides, the formed agglomerates of (DSCG-SD / S-
1915) may have been more compact than (DSCG-JM / S-1915) to be able to give 7% 
more fines by reaching stage 2 on the NGI.  
DSCG-SD / L-4913 DSCG-JM / L-4913 
  
DSCG-SD / M-2914 DSCG-JM / M-2914 
  
DSCG-SD / S-1915 DSCG-JM / S-1915 
  
Figure ‎5-11: DSCG - NGI stage distribution at 100L/min by Aerolizer (n=3) 
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5.2.4 SEM 
Morphology of particles in blends was detected under different magnification 
power of a scanning electron microscope to observe the interaction between API’s 
and trehalose particles. Images shown in Figure ‎5-12 are for blends of different 
trehalose qualities that showed different morphological agglomerations with each 
tested API resulting in different aerosolization performances as previously illustrated. 
In (BU-SD / M-2914), large agglomerates of differently sized spherical particles were 
observed. Zooming in shows that the hydrophobic BU have smaller sized semi 
spheres with concave sides that gave a loose structure in combination with the 
relatively larger spherical trehalose carrier particles. In (BU-JM / M-2914), smaller 
agglomerates were observed compared to the previous. However zooming in shows 
that the irregularly shaped BU fine particles were scattered with high surface contact 
on the obviously larger spherical trehalose carrier particles. Relative to the 
aerosolization performance observed earlier, BU-SD was easier to de-agglomerate 
from the spherical trehalose particles and disperse than the BU-JM. In (BU-SD / TR5) 
and (BU-SD / TR1010), small agglomerates that were connected in an irregular loose 
structure were observed. Zooming in, showed that each TR5 irregular particle had 
higher surface contact with more BU-SD particles than the finer TR1010 particles in 
the other blend. This was previously demonstrated by the tested aerosolization 
performance of the fine TR1010 in releasing highest FPF of BU-SD.  
Generally for the hydrophilic drugs (SS and DSCG), they showed more 
compact or denser agglomerates in combination with the hydrophilic trehalose carrier 
particles due to the higher binding affinity. In (SS-SD / M-2914), agglomerates of 
differently sized spherical particles were observed. The agglomerates were not seen 
as large single units; rather they were smaller dense units. Zooming in, showed that 
SS-SD particles were spherical with some surface corrugation and size variation. 
Larger SS-SD particles were in minimum contact with the spherical trehalose 
particles, but the smaller SS-SD particles filled the small gaps in between leading to a 
tighter arrangement. Indeed, this formulation showed poor aerosolization 
performance as previously examined. In (SS-JM / M-2914), large dense 
agglomerates were observed of rod shaped SS-JM with spherical trehalose particles 
in between. Compared to (SS-SD / M-2914) it showed denser and larger 
agglomerates, nevertheless it gave similar aerosolization performance due to the 
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aerodynamically favored rod shaped SS-JM that may be released off the 
agglomerates’ outer surface upon aerosolization. In (SS-JM / TR5) and (SS-JM / 
TR1010), agglomerates that were connected in an irregular structure were observed. 
Zooming in, shows that the agglomerates are formed by asymmetrical buildup of 
fines from rod shaped SS-JM particles and irregular trehalose particles. In these two 
formulations, the assembly of particles gave the least observed mechanical 
interlocking resulting in better aerosolization performance compared to other SS 
formulations with trehalose. In (SS-JM / REC.M-2914), small dense agglomerates 
were observed of rod shaped SS-JM with spherical trehalose particles in between. 
Zooming in, shows that the rod shaped SS-JM were buildup on surface of the 
partially crystalline trehalose particles that had shaped bridge like formation in 
between spheres. In contrast to the amorphous similarly sized (M-2914), (REC.M-
2914) limited the trapped rods of SS-JM in between the spheres, forming smaller 
agglomerates and resulting in a comparable dispersion performance as the fully 
crystalized Jet milled trehalose. In (DSCG-JM / M-2914), large dense agglomerates 
were observed of irregular shaped DSCG-JM particles alongside with spherical 
trehalose particles.  Zooming in, shows that the highly hygroscopic nature  lead to 
fused particles inside the core of the agglomerates, holding loose fines of DSCG-JM 
on surface. This comes in accordance to the aerosolization performance observed, 
where the large agglomerates were held early by the throat, and fines were able to 
de-agglomerate and disperse.      
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SS-SD / M-2914 
  
SS-JM / M-2914 
 
  
SS-JM / TR5 
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SS-JM / TR1010 
  
SS-JM / REC. M-2914 
 
  
DSCG-JM / M-2914 
 
  
Figure ‎5-12: SEM images under magnification power 1000X (left)  and 5000X (right) of 10 blends 
as listed. 
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5.2.5 Surface energy measurements 
The surface free energy of any material can be classified into non polar forces 
as Van der waals and polar forces such as acid/base interactions. Van der Waals 
forces constitute the major part of the dispersive component of the surface free 
energy (γD) which is a measure for the non-polar interaction sites of a surface. The 
theory developed by (Fowkes, 1964) is the base in calculating (γD), taking into 
account the interaction with the non-polar liquid probes. In this case, the work of 
adhesion is (W = 2 γD). The dispersive surface energy (work of adhesion), is 
expressed in units (J/m2) and the total surface energy is the additive effect of both the 
dispersive (γD) and polar (γp) components (Grimsey et al., 2002). The particle 
molecular nature, size, morphology, surface area, water content, and the processing 
conditions by which it was produced, all governs the resulting surface energy. In a 
number of studies, the aerosolization performance was correlated with the surface 
energy of the particles for both the APIs and the carriers. In general there was an 
inverse relation detected, increasing the total surface energy either dispersive or 
polar forces for various APIs with lactose carrier, decreased the resulting 
aerosolization performance (Das et al., 2009). On the other hand, this surface energy 
can vary between the adsorption strength of particles of the same material 
(Cohesion) or the adsorption strength between particles of different material 
(Adhesion). If particles are highly cohesive or highly adhesive, this will lead to poor 
flowability and dispersibility. Accordingly, some studies used tensile strength method 
and the atomic force microscopy to measure and relate the Cohesion/Adhesion 
balance (CAB) of API particles in regards to the carrier particles. It was perceived 
that a slightly cohesive drug-carrier formulation than being adhesive may give better 
aerosolization performance (Jones et al., 2008). The surface energy measurements 
can be set as a good qualitative method to predict the performance of a new DPI 
formulation.  
The dispersive surface energy (γD) was measured for all API and trehalose 
qualities by IGC. The values shown in Figure ‎5-13 demonstrate the consistency of 
trehalose low (γD) that valued in the range of (40 mJ/m2) under all preparation 
conditions. This similarity can be related to the average particle size of each quality 
that had a close range of D50 from 2.2µm to 9µm. While different trehalose qualities 
of significantly different moisture content, processing condition and morphology did 
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not affect the dispersive surface energy of fine trehalose particles, rather they might 
have affected the polar surface energies. It was considered that the dispersive 
surface energies of the pure material tested an indication for their cohesive 
attractions. On the other hand, the tested (γD) values for APIs showed that spray 
dried qualities were always lower than their jet milled qualities as presented in Figure 
‎5-14. Furthermore, both qualities of the DSCG particles showed the highest 
measured (γD) of about (70 mJ/m2). This was in agreement to their highly 
hygroscopic nature and observed poor flowability resembling high cohesive 
attractions. The measured (γD) of SS-JM was about (58 mJ/m2) resembling 
intermediate cohesive attractions, while SS-SD particles showed the lowest 
measured (γD) of (42 mJ/m2) resembling relatively lowest cohesive attractions. As for 
the hydrophobic BU-JM and BU-SD, both showed relatively intermediate cohesive 
attractions as presented by the measured (γD) of (60 mJ/m2 and 53 mJ/m2) 
respectively.  
In regards of the hydrophilic API aerosolization behavior previously discussed, 
highly cohesive material as DSCG formed strong agglomerates and showed poor 
dispersibility upon aerosolization. Although DSCG can adhere to trehalose due to 
hydrophilic affinity (polar interaction), yet the adhesion force was not enough to 
overcome the cohesion forces and disperse the fines efficiently. In contrast, SS-SD 
having lowest dispersive surface energy showed lowest cohesion forces and higher 
adhesion forces when in formulation with trehalose particles. This also resulted in 
reduced observed flowability and dispersibility. SS-JM carrier free particles having an 
intermediate dispersive surface energy, showed the highest achieved dispersibility for 
a hydrophilic drug, signifying a balance between the particles’ cohesive and adhesive 
forces. SS-JM in formulation with trehalose particles as carrier, have showed a 
reduced aerosolization performance from the carrier free formula. This indicates the 
increased adhesion forces of SS-JM to the trehalose particles due to hydrophilic 
affinity, overcoming the cohesion forces thus resulted in lower dispersibility. In 
regards of the hydrophobic BU qualities, BU-SD presented relatively intermediate 
cohesive forces, while BU-JM had higher dispersive surface energy and thus higher 
cohesive forces. BU-SD carrier free formulation recorded the highest achieved 
aerosolization performance in terms of FPF%. This indicates the most achieved 
balanced cohesion and adhesion forces for optimum dispersibility. Trehalose 
particles in blend with BU-SD might have increased the adhesion slightly over the 
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cohesion in balance, resulting in a general reduction in performance but still with 
excellent dispersibility values. BU-JM behavior was similar with an overall reduced 
dispersibility compared to BU-SD due to the higher cohesive attraction forces noted.  
 
Figure ‎5-13: Dispersive surface energy of different JM and SD trehalose batches 
 
Figure ‎5-14: Dispersive surface energy of JM and SD qualities of BU, SS and DSCG 
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5.3 Discussion 
A DPI carrier potentiality is mainly determined in-vitro by cascade impaction to 
observe the achieved aerodynamic aerosolization performance in terms of dispersed 
fine particle fraction. After the successful production of the inhalable trehalose 
particles in two qualities by spray drying and jet milling, cascade impaction proved 
that fine trehalose particles can achieve excellent aerosolization performance in 
different DPI formulations. The performance study distinguished between the 
different trehalose batches based on the prepared particle morphology, PSD, 
hygroscopicity and surface energy under constant factors as flow rate, inhaler device 
and drug ratio in formulations. 
Despite the PSD differences, the jet milled trehalose quality that showed 
irregular morphology with rougher surface than the SD quality lead to better 
aerosolization performance dispersing both the hydrophobic BU model drug and the 
hydrophilic SS model drug from prepared formulations. The concurrent steps of the 
formulations aerosolization can be briefed in particle fluidization, then drug dispersion 
and final deposition. It was observed that particle morphology in terms of 
aerodynamics had a great impact on the fluidization threshold and dispersion. 
Indeed, at similar particle size distribution, rod shaped particles of the hydrophilic SS 
were easier to fluidize and disperse compared to the spherical particles. Besides, 
hydrophobic BU particles in the concaved spheres morphology were slightly easier to 
fluidize than the irregular shaped fine particles. Additionally the morphological 
influence on aerosolization performance was interconnected with the crystallinity and 
hygroscopicity of the particles. The jet milled trehalose qualities showed crystalline 
less hygroscopic nature that had lower binding affinity to APIs compared to the 
amorphous SD quality. This was further proved when the partially recrystallized 
trehalose spherical particles showed improved aerosolization performance with SS 
compared to the amorphous spherical particles.   
 In case of formulations with 20% hydrophobic BU, all of the trehalose fine 
particle batches either SD or JM showed very good performance over 50% FPF. 
From the presented results, the finest jet milled trehalose particles that had a similar 
size range as the BU particles performed best with 81% FPF delivering 750µg fine 
dose. When considering the formulation of 20% hydrophilic SS, again the jet milled 
trehalose particles performed best, but with least variation between the relatively 
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large and small PSD batches (TR-5) and (TR1010) respectively. Both jet milled 
grades dispersed SS particles in the range of 50% FPF delivering 370µg fine dose. In 
general, the overall performance of the finest trehalose particles showed best 
dispersion behavior with the hydrophobic BU and the hydrophilic SS. On top, the 
carrier PSD influence on the aerosolization performance was interconnected to the 
APIs’ particles surface energies either dispersive surface energy or polar interactions. 
In general fine particles possess high contact surface area that gives high dispersive 
surface energy. However, high surface energy does not necessarily mean poor 
dispersibility, it can relate to a high cohesive force that can be balanced with an 
opposing adhesion force to optimize the aerosolization performance. Hydrophobic 
BU particles exhibited adhesion attractions to the fine trehalose particles that 
balanced the intermediate cohesive forces resulting in small agglomerates that are 
easily dispersed upon aerosolization. On the other hand, hydrophilic SS-JM particles 
exhibited stronger adhesion attractions to the fine trehalose particles that slightly 
exceeded the intermediate cohesive forces, resulting in larger agglomerates with 
lower dispersibility compared to BU formulations. Furthermore, SS-SD particles 
showed least cohesion forces that were highly exceeded by the adhesion attractions 
when in blend with fine trehalose leading to poor dispersibility. As for the DSCG 
particles, the exceedingly high cohesive forces lead to capsule release failure upon 
aerosolization. This behavior was counteracted by high adhesion attractions 
exhibited by the addition of SD-trehalose particles in binary blends. However the 
cohesion/adhesion interactions were not balanced enough to disperse DSCG 
efficiently from the prepared formulations.  
From the results and observations of this chapter, hydrophobic API as BU with 
inhalable particle size of less than 5µm, carrying relatively intermediate dispersive 
surface energy, may have given best reached aerosolization performance in 
combination with hydrophilic irregularly shaped carrier particles of trehalose in a 
similar fine particle size distribution. These formulations have showed least 
mechanical interlocking and van der Waals interactions that lead to optimum aerosol 
generation.  On the other hand, the SS hydrophilic API model has shown most 
excellent results when in crystalline rod shaped particles again with the fine 
hydrophilic irregularly shaped carrier particles of trehalose. Nevertheless, hydrophilic 
API had more affinity to agglomerate and bind to the trehalose particles. As also 
investigated, the amorphous spherical fine particles of trehalose have shown 
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excellent aerosolization performance of formulations with the hydrophobic BU and 
was effective to reduce entrainment of highly hygroscopic DSCG. It is still slightly less 
performing compared to its crystalline irregular shaped particles, but now it might 
have potential with highly cohesive API particles for its added adhesion counter 
attractions. 
In summary, optimum dispersibility and aerosolization performance, is 
achievable by balancing the formulations’ cohesion-adhesion attractions. Certainly 
the interactions between particles are not limited to the total surface energy 
measured by IGC, but also to the positioning and orientation of the particles in 
contact based on morphology and size. Thus deviations from predicted performances 
by energy measurements can be practical by aerosolization performance studies. 
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6. Conclusion and future perspectives 
Dry powder inhalation therapy with all its enumerated advantages is one of the 
most attractive pharmaceutical fields for development in treatment of many 
pathological diseases. The developmental processes targeting optimal aerosol 
generation are mainly focusing on two directions; developing an efficient dry powder 
formulation and developing an inhaler device with efficient mechanism. The study 
aims to utilize trehalose particles as an inert fine carrier to improve DPI aerosolization 
performance, diversify the potential delivery of new drugs in DPI formulations and the 
feasibility of bringing high drug dose into the lungs. In view of that, fine jet milled 
trehalose of different size qualities were produced, characterized and evaluated for 
optimized aerosolization of high OP dose in binary dry powder inhalation 
formulations. Hereafter, surface engineered particles of trehalose were produced by 
simple spray drying methodology and physicochemically characterized. 
Subsequently, the aerosolization behavior of fine spray dried and fine jet milled 
trehalose carrier based DPI formulations were assessed with low dose model 
pulmonary drugs under constant factors as flow rate, inhaler device and drug ratio in 
formulations. The aerosolization performance was correlated to the in formulation 
particles’ morphology, size, hygroscopicity and surface energy.  
Particle surface properties have an influential role in the performance variation 
between different produced batches. In general, jet milling lead to surface 
heterogeneity of particles implying a non-homogenous energy distribution and 
morphology. Two strategies regarding the de-agglomeration behavior of the particles 
can be concluded from the results of this study. First, active sites with high energy 
have higher preference to bind strongly with the API small particles than the surface 
sites with lower energy. Accordingly for the high OP dose formulation evaluated, the 
few high energy active sites of the fine trehalose particles would be saturated easily 
and the majority of the OP particles are binding relatively loose to the less energetic 
surface sites leading to lower adhesion and easier de-agglomeration. Secondly, 
irregular shaped particles or rough particles with asperities may lead to strong 
binding between particles by mechanical interlocking or it may limit the closeness of 
two particles and reduce the Van der Waals forces. It can be assumed that the 
irregular shaped fine particles of the trehalose reduced both the mechanical 
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interlocking and the Van der Waals forces by being placed into the higher ratio of the 
fine rod shaped OP particles. This would be achieved by introducing air space in 
between the particles that facilitate the de-agglomeration process upon 
aerosolization.       
The production of smooth spherical SD trehalose particles was successful in 
the desired particle size range. The particles produced were amorphous particles 
which can be considered as an inferior option in terms of physical DPI carrier stability 
compared to the crystalline particles of trehalose. In trial to produce more stable 
crystalline particles, only partial recrystallization of the smooth spherical SD trehalose 
particles was achieved, maintaining the produced morphology and size range. Full 
crystallization of spherical smooth particles could not be achieved due to the 
formation of sticky stones like structures instead of the required flowing powder 
particles under further exposure to the crystallization conditions. 
Fine trehalose particles that are in similar range as the API, can be very 
effective as carriers to disperse the drug fines from small fluidized agglomerates of 
low dose drugs. However crystalline, less hygroscopic trehalose carriers are 
preferred for their reduced polar interactions resulting in reduced adhesion attraction 
for the API. Furthermore, the morphology of the API particles has two important 
impacts; the ease of fluidization based on its aerodynamics and the positioning for 
reduced mechanical interlocking. Hydrophobic API as BU with inhalable particle size 
of less than 5µm, carrying relatively intermediate dispersive surface energy, may 
have given best reached aerosolization performance in combination with hydrophilic 
irregularly shaped carrier particles of trehalose in a similar fine particle size 
distribution. These formulations have showed least mechanical interlocking and van 
der Waals interactions that lead to optimum aerosol generation.  On the other hand, 
the SS hydrophilic API model has shown most excellent results when in crystalline 
rod shaped particles again with the fine hydrophilic irregularly shaped carrier particles 
of trehalose. Nevertheless, hydrophilic API had more affinity to agglomerate and bind 
to the trehalose particles. As also investigated, the amorphous spherical fine particles 
of trehalose have shown excellent aerosolization performance of formulations with 
the hydrophobic BU and was effective to reduce entrainment of highly hygroscopic 
DSCG. It is still slightly less performing compared to its crystalline irregular shaped 
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particles, but now it might have potential with highly cohesive API particles for its 
added adhesion counter attractions. 
In conclusion, we have come to an understanding that many interconnected 
factors significantly influence the aerosolization performance of various API 
formulations in DPI. In line with the formulation development, Jet milled Trehalose 
dihydrate crystalline particles have been proven as a strong potential for inert DPI 
formulation carrier. It has the capacity to aerosolize different API types at different 
binary ratios attaining excellent performance using low and medium resistance 
inhaler devices. The emphasis on studying different DPI carriers as trehalose has set 
new formulation approaches and options which will definitely lead to the introduction 
of new drugs through the inhalation rout leading to enhanced systematic and local 
therapy. 
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7. German Abstract 
Die Studie hat zum Ziel, Trehalose-Partikel als inerte, feine Träger zu nutzen, 
um die  die Aerosolisierung in Pulvern zur Inhalation zu verbessern. Die Studie zielt 
auch darauf ab, die Formulierung von neuen Wirkstoffen in Trockenpulverinhalaten 
zu vereinfachen und die Möglichkeit zu erforschen, hohe Wirkstoffdosen auf diese 
Weise in die Lunge zu bringen. Feine Trehalose-Partikel wurden durch Strahlmühlen 
und Sprühtrocknung erzeugt, um unterschiedliche physikalisch-chemische 
Eigenschaften zu erreichen. Die Trehalosepartikel wurden im Weiteren mit 
Modellarzneistoffen in trägerbasierten Mischungen formuliert und hinsichtlich ihrer 
aerodynamischen Eigenschaften untersucht. Die Gabe einerhohen Dosis von 
Oseltamivir, einem antiviralen Medikament, wurde weiter verbessert und in 
Präparaten mit 25% feinen Trehalose-Teilchen konnte eine Feinpartikelfraktion von 
etwa 75%  erreicht werden (Bestimmung mit dem Kaskadenimpaktor). Die 
Dispergierung von Modellarzneistoffen  wurde auf Basis ihrer hydrophilen und 
hydrophoben Eigenschaften und dem Einfluss dieser Parameter auf das 
Agglomerationsverhalten mit feinen Trehalosepartikeln ausgewertet.  
Dementsprechend zeigen Trehalose-basierte Mischungen in Abhängigkeit von den 
physikochemischen Eigenschaften der Trehalosepartikel (Teilchengröße, 
Morphologie, Oberflächenenergie, Kristallinität und Hydratation) eine Variabilität in 
der Feinpartikelfraktion zwischen 1% und 80%. Zusammenfassend sind 
maßgeschneiderte DPI-Präparate wesentlich für jeden Wirkstoff und die 
Partikeltechnik, sowohl des  Trägers wie des Wirkstoffs, bestimmt die 
Leistungsfähigkeit der Präparate. Trehalose-Teilchen zeigen Kompatibilität, Stabilität 
und ein gutes Dispergierverhalten mit einer Vielzahl von Wirkstoffen und 
Wirkstoffdosen. Es wird geschlussfolgert, dass feine Trehalose - Teilchen das 
Potenzial haben, hervorragende, inerte und sichere Träger für die Formulierung von 
neuen und bekannten Wirkstoffen in DPI- Präparaten zu sein. 
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Appendix 
A. List of Abbreviations 
API Active pharmacetical ingredient 
BET Brunauer–Emmett–Teller (theory) 
BU Budesonide  
COPD Chronic obstructive pulmonary diseases  
DOE Design of experiment 
DPI Dry powder inhalers  
DSC Differential scanning calorimeter 
DSCG Disodium cromoglycate 
DVS Dynamic vapor sorption 
ERV expiratory reserve volume 
FID Flame ionization detector  
FPD Fine particle dose 
FPF Fine particle fraction 
IGC Inverse gas chromatography  
IRV Inspiratory reserve volume  
JM Jet mill  
MMAD mean median aerodynamic diameter 
OP Oseltamivir phosphate 
pMDI pressurized Metered dose inhalers 
PSD Particle size distribution 
RH Relative humidity  
RSD Relative standard deviation 
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RV Residual volume  
SA Surface area  
SCF Supercritical fluid technologies  
SD Spray drying  
SEM Scanning electron microscope 
SFD Spray freeze drying 
SS Salbutamol sulphate 
TGA Thermo gravimetric analysis  
TLC Total lung capacity  
TR Trehalose 
VC Vital capacity  
XRPD 
 
 
 
 
 
 
 
 
 
 
 
X-ray powder diffraction   
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C. List of Materials 
Brij 35 ICI specialty chemicals, Essen, Germany 
 
Budesonide Shanghai Hengtian Pharmaceutical Co. 
Ltd., Shanghai, China 
 
bidistilled water Freshly produced with the in-house Finn 
Aqua 75, San-Asalo – Sohlberg corp., 
Helsinki, Finland 
 
Disodium Cromoglycate 
(Batch #: 4050/09/07) 
Welding GmbH & CO. KG, Hamburg, 
Germany 
 
Ethanol (96%) Merck, KGaA, Darmstadt, Germany 
 
Glycerol Merck, KGaA, Darmstadt, Germany 
 
Methanol –HPLC Grade J.T. Baker, Deventer, The Nethrelands 
  
O-Phosphoric acid Merck KGaA. Darmstadt, Germany 
 
Oseltamivir phosphate (OP)  Nile Co. for Pharmaceuticals and chemical 
industries, Cairo, Egypt 
 
Potassium dihydrogen phosphate FAGRON, Barsbüttel, Germany 
Salbutamol Sulphate Lusochimica S.P.A. Lomagna, Italy 
 
Triethylamine (99%) Sigma Aldrich Chemie GmbH, Steinheim, 
Germany 
 
Trehalose (TREHA™) 
(C12H26O13; molecular weight, 
378.33g/mol; ≥98.5% purity) 
Cargill, Deutschland GmbH 
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D. List of Equipment 
 
Büchi B-290 Mini spray dryer 
 
 
Büchi Labortechnik AG, Switzerland 
Next Generation Cascade Impactor Copley Scientific, USA 
 
Climate controlled chamber Developed by Imtech and operated by 
Siemens Simatic touch panel to control 
temperature and RH%. 
 
Critical flow controller TPK  
 
Copley Scientific, USA 
Differential scanning calorimeter 
 
Diamond DSC, Perkin Elmer, USA 
Dynamic Vapor Sorption DVS-HT, surface measurement systems 
Ltd., London, UK 
 
Flow meter 
 
Copley Scientific, USA 
FT4 Powder Rheometer 
 
Freeman Technology, UK 
Gas sorption analyzer NOVA 2200, Quantachrome Corporation, 
USA 
 
Helos-Laser diffraction Aerosol dispersing units are RODOS and 
INHALER modules, Sympatec GmbH 
―System-Partikel-Technik‖, Germany. 
 
IGC column packer Surface Measurement Systems, USA 
 
Inverse Gas Chromatography (IGC) 
 
Surface Measurement Systems ―IGC 
2000 SMS‖, USA 
 
Jet-mill  Aljet mill, Fluid Energy processing and 
equipment company, USA. 
 
Mass Comparator balance 
 
AT-106 comparator, Mettler Toledo, USA 
Scaninig electron microscope (SEM) Ultra Plus SEM, Carl Zeiss NTS GmbH, 
Oberkochen, Germany 
Thermo-gravimetric analysis 
 
TGA - TAC7/DX – Perkin Elmer, USA 
Turbula mixer Turbula T2C, Willy A Bachofen AG, 
Basel, Switzerland 
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UNI-Haler  
(Patent no. DE 10 2009 037 840.5) 
Newly developed Inhaler at the 
Department of Pharmaceutics & 
Biopharmaceutics, Kiel, Germany. 
 
UV/VIS-Spectrophotometer 
 
Lambda 40, Perkin Elmer instruments, 
USA 
 
Vacuum Pump HCP5 Copley Scientific, USA 
 
X-ray diffractometer  Stoe and Cie GmbH, Darmstadt, 
Germany 
 
 
 
 
 
 
 
 
 
 
References 
101 
8. References 
Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., Sarmento, B., 2013. 
Nanotechnology and pulmonary delivery to overcome resistance in infectious 
diseases. Advanced drug delivery reviews 65 (13-14), 1816–1827. 
Ashurst, I., Malton, A., Prime, D., Sumby, B., 2000. Latest advances in the 
development of dry powder inhalers. Pharmaceutical Science & Technology 
Today 3 (7), 246–256. 
Aziz, S., 2011. Novel Delivery of Oseltamivir Phosphate Dry Powder Inhalation – 
Formulation and In-Vitro Characterization, Cairo, Egypt. 
Barrett, K.E., Ganong, W.F., 2010. Ganong's review of medical physiology, 23rd ed. 
ed. McGraw-Hill Medical, New York, 1 online resource (ix, 714. 
Beck-Broichsitter, M., Gauss, J., Packhaeuser, C.B., Lahnstein, K., Schmehl, T., 
Seeger, W., Kissel, T., Gessler, T., 2009. Pulmonary drug delivery with 
aerosolizable nanoparticles in an ex vivo lung model. International journal of 
pharmaceutics 367 (1-2), 169–178. 
Beigel, J., Bray, M., 2008. Current and future antiviral therapy of severe seasonal and 
avian influenza. Antiviral Research 78 (1), 91–102. 
Braun, M.A., Oschmann, R., Schmidt, P., 1996. Influence of excipients and storage 
humidity on the deposition of disodium cromoglycate (DSCG) in the Twin 
Impinger. International journal of pharmaceutics 135 (1-2), 53–62. 
Chew, Nora Y K, Tang, P., Chan, H.-K., Raper, J.A., 2005. How much particle 
surface corrugation is sufficient to improve aerosol performance of powders? 
Pharmaceutical research 22 (1), 148–152. 
Claus, S., Weiler, C., Schiewe, J., Friess, W., 2014. How can we bring high drug 
doses to the lung? European journal of pharmaceutics and biopharmaceutics : 
official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 
86 (1), 1–6. 
Clercq, E. de, 2006. Antiviral agents active against influenza A viruses. Nature 
reviews. Drug discovery 5 (12), 1015–1025. 
Cline, D., Dalby, R., 2002. Predicting the quality of powders for inhalation from 
surface energy and area. Pharmaceutical research 19 (9), 1274–1277. 
References 
102 
Cordts, E., Steckel, H., 2012. Capabilities and limitations of using powder rheology 
and permeability to predict dry powder inhaler performance. European journal of 
pharmaceutics and biopharmaceutics 82 (2), 417–423. 
Costanzo, L.S., 2006. Physiology, 3rd ed ed. Saunders Elsevier, Philadelphia, PA, xi, 
490. 
Das, S., Larson, I., Young, P., Stewart, P., 2009. Surface energy changes and their 
relationship with the dispersibility of salmeterol xinafoate powders for inhalation 
after storage at high RH. European journal of pharmaceutical sciences : official 
journal of the European Federation for Pharmaceutical Sciences 38 (4), 347–354. 
Despopoulos, A., Silbernagl, S., 2003. Color atlas of physiology, 5 // 5th ed., 
completely rev. and expanded ed. Georg Thieme Verlag; Thieme, Stuttgart, xiii, 
436. 
Dolovich, M.B., Dhand, R., 2011. Aerosol drug delivery: developments in device 
design and clinical use. The Lancet 377 (9770), 1032–1045. 
Dreitlein, W.B., Maratos, J., Brocavich, J., 2001. Zanamivir and oseltamivir: two new 
options for the treatment and prevention of influenza. Clinical Therapeutics 23 (3), 
327–355. 
Duddu, S.P., Sisk, S.A., Walter, Y.H., Tarara, T.E., Trimble, K.R., Clark, A.R., Eldon, 
M.A., Elton, R.C., Pickford, M., Hirst, P.H., Newman, S.P., Weers, J.G., 2002. 
Improved lung delivery from a passive dry powder inhaler using an Engineered 
PulmoSphere powder. Pharmaceutical research 19 (5), 689–695. 
Dutkowski, R., Smith, J.R., Davies, B.E., 2010. Safety and pharmacokinetics of 
oseltamivir at standard and high dosages. International journal of antimicrobial 
agents 35 (5), 461–467. 
Eisenberg, E., 2007. Case Study: Oseltamivir: An Orally Bioavailable Ester Prodrug 
of Oseltamivir Carboxylate, in: Stella, V., Borchardt, R., Hageman, M., Oliyai, R., 
Maag, H., Tilley, J. (Eds.), Prodrugs, V. Springer New York, pp. 1323-1334. 
Englund, J.A., 2002. Antiviral therapy of influenza. Seminars in pediatric infectious 
diseases 13 (2), 120–128. 
Florence, A.T., Siepmann, J., 2009. Modern pharmaceutics, 5. ed ed. Informa 
Healthcare USA, New York, 2 bd. 
Forbes, B., Ehrhardt, C., 2005. Human respiratory epithelial cell culture for drug 
delivery applications. European journal of pharmaceutics and biopharmaceutics : 
References 
103 
official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 
60 (2), 193–205. 
Fowkes, F.M., 1964. ATTRACTIVE FORCES AT INTERFACES. Ind. Eng. Chem. 56 
(12), 40–52. 
Furuki, T., Kishi, A., Sakurai, M., 2005. De- and rehydration behavior of alpha,alpha-
trehalose dihydrate under humidity-controlled atmospheres. Carbohydrate 
Research 340 (3), 429–438. 
Geller, D.E., 2005. Comparing clinical features of the nebulizer, metered-dose 
inhaler, and dry powder inhaler. Respiratory care 50 (10), 1313-21; discussion 
1321-2. 
Gill, P., Moghadam, T.T., Ranjbar, B., 2010. Differential scanning calorimetry 
techniques: applications in biology and nanoscience. Journal of biomolecular 
techniques : JBT 21 (4), 167–193. 
Gillissen, A., Höffken, G., 2002. Early therapy with the neuraminidase inhibitor 
oseltamivir maximizes its efficacy in influenza treatment. Medical microbiology 
and immunology 191 (3-4), 165–168. 
Gradon, L., Sosnowski, T.R., 2014. Formation of particles for dry powder inhalers. 
Advanced Powder Technology 25 (1), 43–55. 
Grimsey, I.M., Feeley, J.C., York, P., 2002. Analysis of the surface energy of 
pharmaceutical powders by inverse gas chromatography. Journal of 
pharmaceutical sciences 91 (2), 571–583. 
Hassan, M.S., Lau, R., 2011. Inhalation performance of pollen-shape carrier in dry 
powder formulation: effect of size and surface morphology. International journal of 
pharmaceutics 413 (1-2), 93–102. 
Heyder, J., Gebhart, J., Rudolf, G., Schiller, C., Stahlhofen, W., 1986. Deposition of 
particles in the human respiratory tract in the size range 0.005–15 μm. Journal of 
Aerosol Science 17 (5), 811–825. 
Hosokawa, M., 2008. Structure and catalytic properties of carboxylesterase isozymes 
involved in metabolic activation of prodrugs. Molecules (Basel, Switzerland) 13 
(2), 412–431. 
Islam, N., Cleary, M.J., 2012. Developing an efficient and reliable dry powder inhaler 
for pulmonary drug delivery – A review for multidisciplinary researchers. Medical 
engineering & physics 34 (4), 409–427. 
References 
104 
Islam, N., Gladki, E., 2008. Dry powder inhalers (DPIs)--a review of device reliability 
and innovation. International journal of pharmaceutics 360 (1-2), 1–11. 
Jain, N.K., Roy, I., 2009. Effect of trehalose on protein structure. Protein science : a 
publication of the Protein Society 18 (1), 24–36. 
Jones, M.D., Harris, H., Hooton, J.C., Shur, J., King, G.S., Mathoulin, C.A., Nichol, 
K., Smith, T.L., Dawson, M.L., Ferrie, A.R., Price, R., 2008. An investigation into 
the relationship between carrier-based dry powder inhalation performance and 
formulation cohesive-adhesive force balances. European journal of pharmaceutics 
and biopharmaceutics : official journal of Arbeitsgemeinschaft für 
Pharmazeutische Verfahrenstechnik e.V 69 (2), 496–507. 
Jones, M.D., Hooton, J.C., Dawson, M.L., Ferrie, A.R., Price, R., 2006. Dehydration 
of trehalose dihydrate at low relative humidity and ambient temperature. 
International journal of pharmaceutics 313 (1-2), 87–98. 
Jones, M.D., Santo, João G F, Yakub, B., Dennison, M., Master, H., Buckton, G., 
2010. The relationship between drug concentration, mixing time, blending order 
and ternary dry powder inhalation performance. International journal of 
pharmaceutics 391 (1-2), 137–147. 
Kaialy, W., Alhalaweh, A., Velaga, S.P., Nokhodchi, A., 2012. Influence of lactose 
carrier particle size on the aerosol performance of budesonide from a dry powder 
inhaler. Powder Technology, 74–85. 
Kaialy, W., Momin, M.N., Ticehurst, M.D., Murphy, J., Nokhodchi, A., 2010. 
Engineered mannitol as an alternative carrier to enhance deep lung penetration of 
salbutamol sulphate from dry powder inhaler. Colloids and surfaces. B, 
Biointerfaces 79 (2), 345–356. 
Kawashima, Y., Serigano, T., Hino, T., Yamamoto, H., Takeuchi, H., 1998. Effect of 
surface morphology of carrier lactose on dry powder inhalation property of 
pranlukast hydrate. International journal of pharmaceutics 172 (1-2), 179–188. 
Kou, X., Chan, L.W., Steckel, H., Heng, Paul W S, 2012. Physico-chemical aspects 
of lactose for inhalation. Advanced drug delivery reviews 64 (3), 220–232. 
Lahnstein, K., Schmehl, T., Rüsch, U., Rieger, M., Seeger, W., Gessler, T., 2008. 
Pulmonary absorption of aerosolized fluorescent markers in the isolated rabbit 
lung. International journal of pharmaceutics 351 (1-2), 158–164. 
References 
105 
Larhrib, H., Martin, G.P., Marriott, C., Prime, D., 2003. The influence of carrier and 
drug morphology on drug delivery from dry powder formulations. International 
journal of pharmaceutics 257 (1-2), 283–296. 
Li, X., Mansour, H.M., 2011. Physicochemical characterization and water vapor 
sorption of organic solution advanced spray-dried inhalable trehalose 
microparticles and nanoparticles for targeted dry powder pulmonary inhalation 
delivery. AAPS PharmSciTech 12 (4), 1420–1430. 
Li, X., Vogt, F.G., Hayes, D., Mansour, H.M., 2014. Design, characterization, and 
aerosol dispersion performance modeling of advanced spray-dried 
microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery 
as dry powder inhalers. Journal of aerosol medicine and pulmonary drug delivery 
27 (2), 81–93. 
Lindemann, L., Jacobsen, H., Schuhbauer, D., Knoflach, F., Gatti, S., Wettstein, J.G., 
Loetscher, H., Chu, T., Ebeling, M., Paulson, J.C., Prinssen, E., Brockhaus, M., 
2010. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) 
and active metabolite. European journal of pharmacology 628 (1-3), 6–10. 
Littringer, E., Mescher, A., Schroettner, H., Achelis, L., Walzel, P., Urbanetz, N., 
2012. Spray dried mannitol carrier particles with tailored surface properties – The 
influence of carrier surface roughness and shape. European journal of 
pharmaceutics and biopharmaceutics 82 (1), 194–204. 
Malcolmson, R.J., Embleton, J.K., 1998. Dry powder formulations for pulmonary 
delivery. Pharmaceutical Science & Technology Today 1 (9), 394–398. 
Mansour, H.M., Xu, Z., Hickey, A.J., 2010. Dry powder aerosols generated by 
standardized entrainment tubes from alternative sugar blends: 3. Trehalose 
dihydrate and D-mannitol carriers. Journal of pharmaceutical sciences 99 (8), 
3430–3441. 
Maury, M., Murphy, K., Kumar, S., Mauerer, A., Lee, G., 2005. Spray-drying of 
proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I 
spectrum of an immunoglobulin G. European journal of pharmaceutics and 
biopharmaceutics 59 (2), 251–261. 
Minne, A., Boireau, H., Horta, M.J., Vanbever, R., 2008. Optimization of the 
aerosolization properties of an inhalation dry powder based on selection of 
excipients. European journal of pharmaceutics and biopharmaceutics 70 (3), 839–
844. 
References 
106 
Nadarassan, D.K., Assi, K.H., Chrystyn, H., 2010. Aerodynamic characteristics of a 
dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen 
Cascade Impactor. European Journal of Pharmaceutical Sciences 39 (5), 348–
354. 
Nandiyanto, A.B., Okuyama, K., 2011. Progress in developing spray-drying methods 
for the production of controlled morphology particles: From the nanometer to 
submicrometer size ranges. Advanced Powder Technology 22 (1), 1–19. 
Nykamp, G., Carstensen, U., Müller, B., 2002. Jet milling—a new technique for 
microparticle preparation. International journal of pharmaceutics 242 (1-2), 79–86. 
Ogáin, O.N., Li, J., Tajber, L., Corrigan, O.I., Healy, A.M., 2011. Particle engineering 
of materials for oral inhalation by dry powder inhalers. I-Particles of sugar 
excipients (trehalose and raffinose) for protein delivery. International journal of 
pharmaceutics 405 (1-2), 23–35. 
Oo, C., Snell, P., Barrett, J., Dorr, A., Liu, B., Wilding, I., 2003. Pharmacokinetics and 
delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon 
using site-specific delivery capsules. International journal of pharmaceutics 257 
(1-2), 297–299. 
Oxford, J.S., Lambkin, R., 1998. Targeting influenza virus neuraminidase—a new 
strategy for antiviral therapy. Drug discovery today 3 (10), 448–456. 
Pilcer, G., Amighi, K., 2010. Formulation strategy and use of excipients in pulmonary 
drug delivery. International journal of pharmaceutics 392 (1-2), 1–19. 
Rahimpour, Y., Kouhsoltani, M., Hamishehkar, H., 2014. Alternative carriers in dry 
powder inhaler formulations. Drug discovery today 19 (5), 618–626. 
Raula, J., Lähde, A., Kauppinen, E.I., 2009. Aerosolization behavior of carrier-free l-
leucine coated salbutamol sulphate powders. International journal of 
pharmaceutics 365 (1-2), 18–25. 
Sanders, M., 2007. Inhalation therapy: an historical review. Primary care respiratory 
journal : journal of the General Practice Airways Group 16 (2), 71–81. 
Schebor, C., Mazzobre, M.F., Buera, M.d., 2010. Glass transition and time-
dependent crystallization behavior of dehydration bioprotectant sugars. 
Carbohydrate Research 345 (2), 303–308. 
Shi, D., Yang, J., Yang, D., LeCluyse, E.L., Black, C., You, L., Akhlaghi, F., Yan, B., 
2006. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human 
carboxylesterase 1, and the activation is inhibited by antiplatelet agent 
References 
107 
clopidogrel. The Journal of pharmacology and experimental therapeutics 319 (3), 
1477–1484. 
Srichana, T., Martin, G., Marriott, C., 1998. Dry powder inhalers: The influence of 
device resistance and powder formulation on drug and lactose deposition in vitro. 
European Journal of Pharmaceutical Sciences 7 (1), 73–80. 
Steckel, H., Bolzen, N., 2004. Alternative sugars as potential carriers for dry powder 
inhalations. International journal of pharmaceutics 270 (1-2), 297–306. 
Steckel, H., Brandes, H.G., 2004. A novel spray-drying technique to produce low 
density particles for pulmonary delivery. International journal of pharmaceutics 
278 (1), 187–195. 
Steckel, H., Müller, B.W., 1997. In vitro evaluation of dry powder inhalers II: influence 
of carrier particle size and concentration on in vitro deposition. International 
journal of pharmaceutics 154 (1), 31–37. 
Stegemann, S., Kopp, S., Borchard, G., Shah, V., Senel, S., Dubey, R., Urbanetz, N., 
Cittero, M., Schoubben, A., Hippchen, C., Cade, D., Fuglsang, A., Morais, J., 
Borgström, L., Farshi, F., Seyfang, K.-H., Hermann, R., van de Putte, A., 
Klebovich, I., Hincal, A., 2013. Developing and advancing dry powder inhalation 
towards enhanced therapeutics. European Journal of Pharmaceutical Sciences 48 
(1-2), 181–194. 
Sussich, F., Cesàro, A., 2008. Trehalose amorphization and recrystallization. 
Carbohydrate Research 343 (15), 2667–2674. 
Sussich, F., Urbani, R., Princivalle, F., Cesàro, A., 1998. Polymorphic Amorphous 
and Crystalline Forms of Trehalose. J. Am. Chem. Soc. 120 (31), 7893–7899. 
Swaminathan, V., Cobb, J., Saracovan, I., 2006. Measurement of the surface energy 
of lubricated pharmaceutical powders by inverse gas chromatography. 
International journal of pharmaceutics 312 (1-2), 158–165. 
Tee, S.K., Marriott, C., Zeng, X.M., Martin, G.P., 2000. The use of different sugars as 
fine and coarse carriers for aerosolised salbutamol sulphate. International journal 
of pharmaceutics 208 (1-2), 111–123. 
Telko, M.J., Hickey, A.J., 2005. Dry powder inhaler formulation. Respiratory care 50 
(9), 1209–1227. 
Thi, T.H., Danède, F., Descamps, M., Flament, M.-P., 2008. Comparison of physical 
and inhalation properties of spray-dried and micronized terbutaline sulphate. 
European journal of pharmaceutics and biopharmaceutics 70 (1), 380–388. 
References 
108 
Tiddens, H.A., Geller, D.E., Challoner, P., Speirs, R.J., Kesser, K.C., Overbeek, S.E., 
Humble, D., Shrewsbury, S.B., Standaert, T.A., 2006. Effect of dry powder inhaler 
resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of 
six years and older. Journal of aerosol medicine : the official journal of the 
International Society for Aerosols in Medicine 19 (4), 456–465. 
Traini, D., Young, P.M., Jones, M., Edge, S., Price, R., 2006. Comparative study of 
erythritol and lactose monohydrate as carriers for inhalation: Atomic force 
microscopy and in vitro correlation. European Journal of Pharmaceutical Sciences 
27 (2-3), 243–251. 
United States Pharmacopeial Convention, 2014. The United States pharmacopeia: 
The national formulary, USP 37 - NF 24 ed. United States Pharmacopeial 
Convention, Rockville, 3 v ; 
Vatsaraj, N.B., Gao, D., Kowalski, D.L., 2003. Optimization of the operating 
conditions of a lab scale Aljet mill using lactose and sucrose: a technical note. 
AAPS PharmSciTech 4 (2), E27. 
Vehring, R., 2008. Pharmaceutical Particle Engineering via Spray Drying. Pharm Res 
25 (5), 999–1022. 
Vehring, R., Foss, W.R., Lechuga-Ballesteros, D., 2007. Particle formation in spray 
drying. Journal of Aerosol Science 38 (7), 728–746. 
Verhoeven, N., Neoh, T.L., Furuta, T., Yamamoto, C., Ohashi, T., Yoshii, H., 2012. 
Characteristics of dehydration kinetics of dihydrate trehalose to its anhydrous form 
in ethanol by DSC. Food Chemistry 132 (4), 1638–1643. 
Vicente, J., Pinto, J., Menezes, J., Gaspar, F., 2013. Fundamental analysis of particle 
formation in spray drying. Powder Technology, 1–7. 
Yang, M.Y., Chan, J.G., Chan, H.-K., 2014. Pulmonary drug delivery by powder 
aerosols. Journal of Controlled Release, 228–240. 
Young, P.M., Cocconi, D., Colombo, P., Bettini, R., Price, R., Steele, D.F., Tobyn, 
M.J., 2002. Characterization of a surface modified dry powder inhalation carrier 
prepared by "particle smoothing". The Journal of pharmacy and pharmacology 54 
(10), 1339–1344. 
Zeng, X.M., Martin, G.P., Marriott, C., Pritchard, J., 2000a. The effects of carrier size 
and morphology on the dispersion of salbutamol sulphate after aerosolization at 
different flow rates. The Journal of pharmacy and pharmacology 52 (10), 1211–
1221. 
References 
109 
Zeng, X.M., Martin, G.P., Marriott, C., Pritchard, J., 2000b. The influence of carrier 
morphology on drug delivery by dry powder inhalers. International journal of 
pharmaceutics 200 (1), 93–106. 
Zhu, H.-J., Markowitz, J.S., 2009. Activation of the antiviral prodrug oseltamivir is 
impaired by two newly identified carboxylesterase 1 variants. Drug metabolism 
and disposition: the biological fate of chemicals 37 (2), 264–267. 
 
 
 
 110 
Acknowledgement  
 
At first, I praise God, from whom all the blessings flow 
I am heartily thankful to my supervisor, Prof. Dr. Hartwig Steckel, whose, 
guidance and support from the initial to the final level of my PhD project enabled me 
to develop skills and understandings in line with my career prospective. 
I owe my deepest gratitude to all the working team in the Pharmaceutics and 
Biopharmaceutics department in Kiel for their continuous support and invaluable 
assistance during my work and stay in Kiel.  Special thanks to Dr. Regina Scherlieβ, 
who showed me support and care in a number of ways making life experiences in 
Kiel go easy and enjoyable. It was an honor for me working with Rudi, for his loving 
and simple attitude of doing complicated technical work support, as he was the 
designer for most of the schematic diagrams in this thesis. As well, I am grateful to 
Mathias, the one who was responsible to take the SEM images for the whole 
department. 
Lastly, I will always be indebted to my parents whom by their love, care and 
support I was able to overcome all challenges and achieve my own dreams. 
 
 
 
 
 
 
 
 
 
 
 111 
Curriculum Vitae 
 
PERSONAL INFORMATION: 
 
   Surname Aziz 
   Name Shahir 
   Place of birth Cairo, Egypt 
   Date of birth 24.12.1986 
   Citizenship Egyptian 
EDUCATION:  
     2012 – 2015 
      
PhD candidate in Pharmaceutics and Bio-
pharmaceutics (Institute of Pharmacy), Christian 
Albrecht University of Kiel, Germany.  
     2010 – 2011 M.Sc. in Pharmaceutical Technology – German 
University in Cairo 
Thesis: ―Novel Delivery of Oseltamivir Phosphate 
in Dry Powder inhalation‖ 
     2003 – 2008 B.Sc. in Pharmacy and Biotechnology (Excellent 
with high honors) – German University in Cairo 
     2001 – 2003  Cambridge International general certificate of 
secondary education (IGCSE) with score 104% in 
2 years – St. Fatima High School.  
WORK EXPERIENCE  
    2011 – 2015 Assistant Lecturer, Pharmaceutical technology 
department, faculty of pharmacy and 
biotechnology, GUC 
Leading Courses: Pharmaceutics I & II 
    2009 – 2011 Teaching  assistant, Pharmaceutical technology 
department, faculty of pharmacy and 
biotechnology, GUC 
 
 
 
 112 
CONFERENCES  
 Respiratory Drug Delivery (RDD) 2012, Phoenix Arizona, USA. 
 Controlled Release Society – Germany Local chapter 2014 meeting, 
University of Kiel. 
 International conference of photodynamic therapy and Nano medicine for 
cancer diagnosis and therapy 2012, German university in Cairo. 
PUBLICATIONS & PRESENTATIONS 
 Poster Presentation and Publication; ―Oseltamivir Phosphate Dry Powder 
Inhalation - Formulation and In-Vitro Characterization‖, Respiratory Drug 
Delivery (2012), Vol. 2, pp 519-524.   
GRANTS AND SCHOLARSHIPS 
 GUC - M.Sc. research grant 2010. 
 DAAD short stay scholarship for M.Sc. practical research at the 
Pharmaceutics and Biopharmaceutics department in Kiel, Germany (2010). 
 GUC - DAAD Conference Grant for RDD 2012.  
AWARDS 
 M.Sc. - Academic Excellence award by Egyptian Pharmacist Syndicate. 
 
